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ABSTRACT 
 
 
 Multiple sclerosis (MS) is the most common demyelinating disorder of the central 
nervous system.  MS is believed to occur in genetically susceptible individuals due to an 
unknown environmental stimulus.  MS patients produce autoantibodies to heterogenous 
nuclear ribonuclearprotein A1 (hnRNP A1), an RNA binding protein (RBP) highly 
expressed in neurons.  hnRNP A1 functions in pre-mRNA splicing, mRNA trafficking, 
and translation.  Furthermore, the anti-hnRNP A1 antibodies are specific to a N-terminal 
region termed ‘M9’ which serves as a nuclear export sequence/nuclear localization 
sequence (NES/NLS) responsible for nuclear/cytoplasmic transport of the protein.  In this 
manuscript we will provide data revealing that anti-hnRNP A1 antibodies enter neuronal 
cells via clathrin-mediated endocytosis.  Moreover, we have shown that anti-hnRNP A1 
antibodies cause redistribution of endogenous hnRNP A1 protein, decrease in cellular 
ATP levels, and increase in apoptosis. Additionally, we present data depicting RNA 
binding partners of hnRNP A1 protein as well as the effect of anti-hnRNP A1 
autoantibodies upon specific RNA binding partners. To further these studies we set out to 
determine the effect of anti-hnRNP A1 antibodies on experimental autoimmune 
encephalomyelitis (EAE), the murine model of MS.  Specifically, we will present the 
effect of anti-hnRNP A1-M9 antibodies on clinical symptoms and neurodegeneration in 
EAE.  Taken together, we present a series of experiments which will depict a journey of 
discovery from the initial discovery of anti-hnRNP A1 antibodies to our present 
understanding of trafficking, deleterious effects, and in vivo effects of anti-hnRNP A1 
antibodies and their implications in the disease Multiple Sclerosis. 
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CHAPTER 1.    INTRODUCTION 
 
 
 This dissertation is a compilation of work I completed in the lab of Dr. Michael 
Levin to fulfill the requirements for a Ph.D. in neuroscience. The background section 
entails a literature review on the role of neurodegeneration in the pathogenesis of 
multiple sclerosis (MS). It includes information on a number of hypotheses about 
neurodegeneration including, but not limited to, work related to my experiments on how 
autoantibodies to the RNA binding protein hnRNP A1 might contribute to 
neurodegeneration in MS. The work has been divided into the following three aims: 
 
 Aim 1, “Anti-hnRNP A1 antibodies penetrate and cause deleterious effects in 
neurons in vitro,” was published in the Journal of Clinical and Cellular 
Immunology 1. 
 
 Aim 2, “Anti-hnRNP A1 antibodies co-localize with RNA granules and alter 
spastic paraplegia genes in neurons,” is a continuation of work describing 
mechanisms by which anti-hnRNP A1 antibodies cause neurodegeneration of 
neurons in vitro. A manuscript based on these experiments is under review by 
Neuroscience Letters. 
 
 Aim 3, “Anti-hnRNP A1 antibodies increase neurodegeneration in 
experimental autoimmune encephalomyelitis (EAE), an animal model of 
MS,” examines how anti-hnRNP A1 antibodies might contribute to 
neurodegeneration in vivo. 
 
 
Multiple Sclerosis 
 
 
Background 
 
 Multiple sclerosis (MS) is a complex autoimmune disease that impairs the central 
nervous system (CNS).  MS is the most common demyelinating disorder of the CNS.  
The neurological disability and clinical course of the disease is highly variable and 
unpredictable from one patient to another. The cause of MS is still unknown but it is 
thought to occur in genetically susceptible individuals who develop disease due to a non-
genetic trigger such as altered metabolism, a virus, or other environmental factors 2.  
Patients with MS generally present to the physician with any of the following symptoms: 
numbness/weakness of limbs, loss/blurred vision, tingling/pain, tremor, slurred speech, 
fatigue, bowel problems, or dizziness.  There are three main clinical types of MS.  First, 
is the relapsing remitting type of MS.  During the relapsing-remitting phase, patients 
experience bouts of neurological symptoms (relapses) which will eventually improve 
partially or completely for months or even years (remissions).  Patients with relapsing-
remitting MS (RRMS) sometimes develop a second phase of disease called secondary 
progressive MS (SPMS) during which they progress to a ‘smoldering’ chronic disease 
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which evolves at a constant rate without remissions.  The third type of MS is primary 
progressive MS (PPMS).  Patients with PPMS present to the physician with initial 
neurological symptoms and from that point onward have a disease course with constant 
‘smoldering’ disease progression without any remissions. MS patients develop 
progressive, irreversible, neurological disability associated with neuronal and axonal 
damage, collectively known as neurodegeneration.  Neurodegeneration in MS involves 
multiple mechanisms including autoimmunity to CNS targets, axonal hypoxia and 
oxidative stress, mitochondrial dysfunction, and disturbances in lipid metabolism and 
nuclear receptors. 3-6  MS has historically been viewed primarily as a white matter 
disease.  However, recent data indicates that both white matter and gray matter 
destruction contribute to its pathogenesis.  While both inflammation and demyelination 
are well-described cellular processes, a diverse pool of any of the following might 
characterize neurodegeneration: neuronal cell death, apoptosis, necrosis, and hypoxia. 
Neurodegeneration was traditionally considered as a secondary phenomenon to 
inflammation and demyelination; however, some neurons undergo apoptosis at earlier 
stages of disease.  Evidence suggests that an overlap between neurodegeneration, 
demyelination, and inflammation cause MS. 
 
 While demyelineation may plan an important role in relapsing remitting stage 
(RRMS), it doesn’t correlate well with progressive forms of the disease. Evidence has 
While demyelineation may play an important role in relapsing remitting stage (RRMS), it 
doesn’t correlate well with progressive forms of the disease. Evidence has suggested that 
the progressive stages of disease correlate more closely with axonal loss. 7,8  Over the 
past several years a major shift in thinking about the pathogenesis of progressive forms of 
MS has occurred.8-20 Axonal loss rather than demyelination has been shown to correlate 
more accurately with clinical disability.18,21 A new concept emerging in the MS literature 
theorizes that axonal loss may be occurring independently of or even be the cause of the 
demyelination in MS.18,21 Evidence indicates that neurodegeneration occurs in all stages 
of the disease.7,9,13,16,22  In addition, neurodegeneration seen in progressive forms of MS 
does not correlate with white matter plaque location, but instead correlates with gray 
matter and cortical pathology.7,9,16,23-27 A post-mortem analysis of spinal cords from MS 
patients showed that axonal loss in white matter tracts did not associate with 
demyelinated plaques in the region.17 This indicates that there might be some 
pathological mechanisms independent of myelin loss that contributes to the axonal loss 
and neurodegeneration present in MS.  Further evidence has shown that axonal injury can 
occur before myelin loss suggesting that axonal injury and neurodegeneration could be 
independent of demyelination and may occur prior to or in parallel with demyelination. 
13,17,18,28 Neurodegeneration is a very complicated process that involves several factors 
associated with the resulting clinical progression in MS patients. 
 
 
Historical Perspective of MS 
 
 The first depiction of the disease which would be known as Multiple Sclerosis 
was illustrated by a Scotsman in 1838.29  The unnamed patient depicted was of French 
origin.  Early on in the discovery of the disease various names and classifications existed.  
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Jean-Martin Charcot (1825-1893), who many agree began the first serous studies on 
demyelinating disorders, referred to the disease as la sclerose en plaques disseminees, la 
sclerose multiloculaire, or la sclerose generalisee.29  These names were translated for the 
English-speaking world at the time as disseminated (cerebrospinal) sclerosis.   
Throughout the early year’s studies of the disease, various nomenclature was used 
throughout England, France, Australia and the new world.  The term which we use today, 
multiple sclerosis originated in Germany.  In Germany the term multiple Sklerose de 
Nervensystems was used from the onset.  Consensus on nomenclatures was ultimately 
achieved in 1955 with the publication of Multiple Sclerosis, written by Douglas 
McAlpine, Nigel Compston, and Charles Lumsden.29   
 
 Throughout the history of MS, various scientific laboratory based findings have 
occurred which shed insight into varying aspects of the disease.  In 1941, Elvin Kabat 
performed the first immunoglobulin G characterization, thus providing evidence of 
intrathecal antibody synthesis in MS patients.29  He further formed the framework for 
complementarity-determining regions of antibodies which led to the molecular basis of 
therapeutic humanization of monoclonal antibodies.  In the modern era, John Whitaker is 
responsible for the revealing the role and specificity of oligoclonal banding in the CSF of 
patients with MS.  In the 1960s new observations begin to implicate glia and 
remyelination in the pathogenesis of MS.29  By the late 1970s Ken Smith and his 
colleagues had provided proof that remyelination can restore conduction.  The studies 
performed during this era which eventually led to the findings by Ken Smith and 
colleagues set the stage for an era of studies aiming to explore the neurobiology of 
remyelination as well as approaches to restore loss of this mechanism.29  More recently 
evidence has come to light which suggests axonal degeneration plays a vital role in the 
pathogenesis of MS8.  As evidenced throughout the history of the disease, MS is a 
multifaceted disease in which novel findings have arisen periodically throughout history 
leading to the understanding we currently have today.     
 
 
Hypoxia 
 
 Over the years, multiple hypotheses have been proposed to explain the 
pathogenesis of MS, ranging from viral infection, cytokine-induced apoptosis and 
oxidative stress to molecular mimicry and metabolic disorders.3,4,30,31 However, none 
successfully identified a single pathological mechanism, likely because MS is a 
heterogeneous disease with a multifaceted etiology.32,33  Although it has not been proven, 
the data presented could lead to the hypothesis that various disease causing entities likely 
lead to the form of MS present within each individual.  
 
 One school of thought suggests MS pathology is due to axonal damage and loss, 
which occurs when chronically demyelinated neurons reach a state of “virtual hypoxia” 
associated with reduced ATP production, ion channel and mitochondrial dysfunction.  It 
is believed that loss of myelin results in an increased energy demand and a relative 
cellular energy deficit, which eventually leads to neuronal death.  In a viable neuron, 
Na+/K+ ATPase is located at Nodes of Ranvier.  Nodes of Ranvier are gaps along the 
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axon where the myelin sheath is not present.  The Nodes of Ranvier conduct the electrical 
impulse along the axon.  The Nodes of Ranvier contain Na+/K+ ATPase, Na+/Ca2+ 
exchangers, and voltage gated Na+ channels that generate action potentials along the 
axon.  Evidence suggests that after demyelination, Na+ channels undergo redistribution 
from a location predominantly on the Nodes of Ranvier to diffusely spread along the 
axon.34,35  Thus, the number of NA+/K+ ATPase increases along a demyelinated axon in 
order to counteract the loss of Na+ channels and continue saltatory conduction.  The 
increase in Na+/K+ ATPase results in an increased energy demand for neuronal firing.  In 
MS patients this increased energy demand cannot be met because of the impaired 
mitochondrial energy production in the CNS.17,28,36  Impaired mitochondrial energy 
production leaves neurons in a depleted energy state, which has been shown to reduce the 
ability of Na+/K+ ATPase function.37  Depleted mitochondrial energy production and 
reduced firing ability in the overpopulated Na+/K+ ATPase within demyelinated neurons 
in MS leads to several deleterious downstream effects, among which is impaired 
neurotransmission.  With a lack of efficient Na+/K+ ATPase, the cell (in theory) should 
enter a state of axonal depolarization.  This state of axonal depolarization causes the 
overpopulated Na+/K+ ATPase to become leaky, resulting in increased intracellular Na+ 
concentrations.  It is believed that if axonal Na+ rises to a concentration greater than 20 
mM, the Na+/Ca+ exchanger will operate in reverse, thus acting as a system to dump Ca2+ 
into the axon.38  The increase in Ca2+ within the axon is known as Ca2+ loading.  
Additional sources may contribute to axonal Ca2+ loading such as release from 
intracellular Ca2+ stores, voltage gated Ca2+ channels, and Ca2+ permeable cation 
channels such as glutamate gated receptors.39-43   Large quantities of glutamate released 
by activated immune cells activate glutamate receptors, which result in axonal Ca2+ 
loading and subsequent neuronal death.44,45 In hypoxic cells reversal of Na+ dependent 
glutamate transporters results in glutamate release.5 In addition, astrocytes can release 
glutamate by exocytosis or hemichannels and unmyelinated callosal axons release 
glutamate in a vesicular manner similar to normal release at the synapse.46-48 This 
increase in vesicular release of glutamate within the white matter has implications for the 
mechanisms of ischemia-induced myelin damage possibly through activation of glial 
cells.46 
 
 Hypoxia might also play a role in formation of MS lesions. Decreased oxygen 
availability (hypoxia) is often seen in tissues at the sites of chronic inflammation. 
Inflamed tissue has increased metabolic activity due to the presence of inflammatory 
cells, poor perfusion related to blood vessel stenosis, and microthrombosis. Therefore, 
chronically inflamed tissue has increased demand and a limited supply of oxygen. This 
imbalance results in hypoxia at inflammatory sites. Hypoxia also increases the 
permeability of the blood brain barrier (BBB) and results in overexpression of pro-
inflammatory genes.49-51 Patients with MS are seen to have increased permeability of the 
BBB.  Hypoxia is often accompanied by hypoperfusion. In about 50% of MS patients, 
blood flow through normal-appearing white matter is reduced.52-56  Taken together, both 
hypoxia and hypoperfusion might be a precipitating factor for MS lesion formation.  
 
 Hypoxia-inducible factor (HIF) is an important transcription factor that regulates 
cellular metabolism and survival under hypoxic stress. HIF is composed of an alpha and 
 5 
beta subunit (HIF-α and HIF-β). Active HIF requires heterodimeric complex formation of 
the two subunits, which then translocate to the nucleus, binds to the hypoxia-response 
element (HRE), and associates with co-activators such as CBP/p300.  The binding results 
in activation or suppression of many genes involved in metabolism and cell survival. 
These changes include an increase in hypoxia-inducible factor-1α (HIF1α) protein levels, 
expression of HIF1- inducible genes in MS brain, blood vessel density and endothelial 
cell proliferation.49,57,58 HIF-1α plays a pro-inflammatory role in cells of the myeloid 
lineage and anti-inflammatory role in intestinal epithelial cells.59,60  Increases in HIF-1α 
could explain the increased inflammation seen in patients with MS, specifically in the 
RRMS stage when a predominantly B and T cell response is present. 
 
 HIFs regulate cellular stress responses in tandem with nuclear factor-kappa ß 
(NF-k-ß) to control hypoxic inflammation through activation of cytokine and hypoxia 
pathways.49  In fact there is a cross talk between these two transcription factors during 
hypoxic inflammation. HIF can be activated in response to multiple stimuli such as 
bacterial lipopolysaccharide, microtubule disruption, interleukin (IL-18) and tumor 
necrosis factor  (TNF-, hepatocyte growth factor and reactive oxygen species (ROS). 
The mechanism of HIF activation involves NF-k-ß dependent up-regulation of HIF-1α 
messenger ribonucleic acid (mRNA) levels.61 HIF-1α contains an active binding site for 
NF-k-ß upstream of the transcription start position.62 A recent study demonstrated that 
NF-k-ß controls the HIF pathway in response to TNF-.63 While NF-k-ß controls HIF-1α 
expression levels, HIF-1α can regulate NF-k-ß signaling. Mice overexpressing HIF-1α 
exhibited increase in pro-inflammatory NF-k-ß targets.64  From data presented, it appears 
that HIFs could play an important role in the pathogenesis of MS.  Although HIFs can act 
in a helpful manner in epithelial cells by acting in an anti-inflammatory manner, HIFs act 
as pro-inflammatory factors in the cells of myeloid lineage such as B and T cells.  By 
acting in a pro-inflammatory manner, HIF alterations could be the source of the increased 
inflammatory cells seen in MS, especially in the RRMS stage when B and T cells 
predominate. Although this theory is not yet fully correlated, additional work within this 
area could spark important insight to the field of MS.  
 
 
Oxidative Stress 
 
 Oxidative Stress (OS) resulting from the formation of reactive oxygen species 
(ROS) secreted primarily by macrophages is believed to play a role in the pathogenesis of 
MS 2.  ROS are free radicals and related molecules, which are defined as any chemical 
species that contain one or more unpaired electrons.3  The most common ROS are 
hydroxyl radical (OH-), superoxide radical (O2-), and nitric oxide (NO) as well as other 
molecules such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO-).  Unpaired 
electrons cause ROS to act as electron acceptors, which results in the stealing of electrons 
by ROS (oxidation).  ROS occur within a normal cell to a certain extent and a number of 
mechanisms are in place to guard against ROS induced damage; however, it appears that 
in patients with MS the ROS exceed the capacity of the cellular defense mechanisms.  
ROS are known to cause damage to lipids, proteins, and DNA leading to cellular death by 
necrosis and apoptosis.  Also, metals such as iron are normally stored within iron binding 
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proteins. However injured cells release iron so it is available to catalyze the free-radical 
reactions of ROS formation.  Other sources of free radical production are due to oxygen 
use in mitochondria and enzymatic pathways such as xanthine oxidase, NADPH oxidase, 
lipoxygenases, and cyclooxygenase.3  The respiratory burst system of activated 
microglia, which are glial cells that act as the immune response of the CNS, have also 
been shown to produce large quantities of ROS. In addition, reactive astrocytes have been 
shown to produce NO.3,65 
 
 Evidence suggests that oxygen and nitrogen free radicals generated by 
macrophages cause demyelination and axonal injury in both EAE and MS.66,67 EAE is an 
animal model of MS in which mice injected with myelin peptides mixed in adjuvant 
exhibit CNS demyelination. Furthermore, free radicals activate transcription factors 
resulting in the up-regulation of the expression of many genes that are associated with 
MS such as NF-k-ß, TNF-α, intracellular adhesion molecule 1 (ICAM-1), and vascular-
cell adhesion molecule 1 (VCAM-1).45,68  A study by Langemann et al., revealed that MS 
plaques had increased free radical activity as well as decreased levels of important 
antioxidants such as glutathione, alpha-tocopherol, and uric acid.69 Further evidence has 
shown that oxidative damage to DNA in MS includes damage to mitochondrial DNA, 
implicating mitochondria not only in the formation of ROS but possibly as a pathway 
directly affected by OS due to the formation of ROS.70 Studies have also shown that 
nitric oxide synthase (NOS) is upregulated in inflammatory lesions and that NO and its 
derivative peroxynitrite inhibit mitochondrial respiration.6,66,71 NO is both essential for 
life and toxic. Its immunomodulatory effect helps sustain healthy homeostasis; however, 
large NO quantities damage axons.6  Inflammation induces the production of NO. 
Excessive generation of NO is an indicator of aging and neurodegeneration. Increased 
NO concentration raises intracellular Ca2+ and Na+ levels and may be responsible for 
mitochondrial dysfunction.6,72  Tissue damage in MS is caused in part by elevated levels 
of NO. In the CNS, NO is produced by macrophages and microglia following the 
induction of nitric oxide synthase (NOS) by the proinflammatory cytokines TNF- and 
INF-.73   Notably, NO has been show to prevent the stabilization of HIF through an 
increase in prolyl hydroxylase dependent mechanism leading to HIF degradation.74,75 
Another oxidative agent, H2O2, decreased HIF-DNA binding capacity and the expression 
of its target genes.76,77 Taken together these studies suggest that redox system plays an 
important role in HIF regulation. 
 
 NO can also react with sulfhydryl groups of proteins resulting in S-nitrosylation 
of target proteins, which initially can act as a protective mechanism in OS to defend 
proteins from degradation. However, increased OS and over accumulation of NO, results 
in irreversible cell damage caused by oxidation of free thiols, nitration of tyrosine 
residues, and lipid peroxidation.78 Increased S-nitrosylation has been detected in normal 
appearing white matter of MS patients’ brain compared to normal controls, indicating 
that nitrosative damage is involved in the pathophysiology of MS.79 
 
 In addition to ROS, glutamate appears to be another major source of OS in the 
brain through the activation of ionotropic glutamate receptors.  It is possible that damage 
induced by free radicals can occur by the stimulation of phospholipase A2 (PLA2) and 
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the release of amino acids, which in the presence of free radicals results in an enhanced 
release of glutamate.80,81 Cerebrospinal fluid (CSF) of MS patients has elevated levels of 
glutamate.82,83 Increased glutamate via interaction with alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors have also shown to be 
deleterious to oligodendrocytes (which appear to be highly vulnerable to glutamate 
excitotoxicity).84,85   Interestingly, AMPA/kainate receptors are known to have increased 
permeability to Ca2+ resulting in Ca2+ loading of cells.86 As the oxidative stress theory 
stands, it appears that ROS in the presence of a weakened antioxidant cellular defense 
results in the damage of cellular components such as lipids, proteins, nucleic acids and 
mitochondrial DNA.  These damaged components alter multiple pathways, associated 
with ATP production, up regulation of genes associated with MS pathology, and increase 
glutamate levels (via AMPA/kainate receptors). 
 
 
Molecular Mimicry 
 
 Molecular mimicry is one mechanism that explains the association between an 
autoimmune response to an environmental agent acting as a contributor to the 
pathogenesis of MS.87-92 The hypothesis of molecular mimicry describes the molecular 
consequences of immunological cross reactivity: when T-cells or antibodies specific for 
an environmental agent (such as a virus) cross react with a host antigen, resulting in 
target cell and organ damage.  Previously it has been shown that patients with HTLV-1 
Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), an HTLV-1 virus 
induced spastic paraparesis clinically similar to MS, produce autoantibodies to the RNA 
binding protein hnRNP A1.93  Similary, it has been presented that patients with MS 
produce antibodies to hnRNP A1, specifically to the M9 region of the protein.94  M9 
serves as the nuclear export sequence/nuclear localization sequence for hnRNP A1. 
1,2,11,12,93-99  Anti-hnRNP A1 antibodies have been shown to produce deleterious effects 
upon neuronal cells.  It has been shown that anti-hnRNP A1 antibodies reduce cellular 
ATP, increase apoptosis, reduce neuronal firing, and cause a redistribution of endogenous 
hnRNP A1 protein. 1,94  Furthermore, transfection of anti-hnRNP A1 antibodies into 
neurons caused changes in transcripts related to A1 function, specifically the spinal 
paraplegia genes (SPGs).12  These findings of altered RNA levels of the SPGs were 
further confirmed in IgG isolated from MS patients compared to controls.12  Additionally, 
we present data supporting anti-hnRNP A1 antibodies role in a “dying back” 
neurodegenerative mechanism in vivo in a murine EAE model of MS.  In summary, 
patients with MS produce autoantibodies to the RNA binding protein hnRNP A1 similar 
to patients with HAM/TSP.  Anti-hnRNP A1 antibodies appear to cause multiple 
deleterious effects both in vitro and in vivo which could provide a possible mechanism 
for the neurodegeneration seen in patients with MS. 
 
 
Antibodies 
 
 Antibodies present in MS patients can be categorized into two major groups 
depending on their target antigens: myelin and non-myelin antibodies. In vitro and in 
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vivo studies suggest that both types of antibodies have some involvement in the 
pathogenesis of MS.11 Anti-myelin antibody targets include myelin oligodendrocyte 
glycoprotein (MOG), myelin basic protein (MBP), myelin-associated glycoprotein 
(MAG), and proteolipid protein (PLP).100-103 These antibodies have been found in sera 
and CSF of MS patients, however the exact role of such myelin antigens in MS remains 
contradictory. One study demonstrated that development of clinically definite MS could 
be predicted based on the presence of anti-MOG and anti-MBP antibodies in patient’s 
sera; others found no association between anti-MOG and anti-MBP antibodies and MS 
progression.104-106 Immunopathogenic effects of anti-myelin antibodies might be epitope 
specific or depend on the antibody confirmation.102,107-109 Early studies did not specify 
cellular pathways affected by autoantibodies, however in a recent study Ho et al., showed 
that MAG autoantibodies targeted the following natural brain lipids: 1-palmitoyl-2-
glutarol-sn-glycero-3-phosphocholine (PGPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
(phospho-L-serine), (POPS), 1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine 
(azPC) and 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (azPC ester).110  
Moreover the authors showed that that POPS, PGPC, azPC, and azPC ester affected 
inflammatory, survival, and apoptotic signaling pathways. Specifically, canonical NF-k-ß 
and extracellular signal–regulated kinase (ERK) pathways were activated in stimulated T-
cells isolated from EAE mice. Overall their data suggests that myelin phospholipids are 
targeted by autoimmune responses in MS. 
 
 A growing number of studies point to the fact that antibody-mediated axonal 
injury could be initiated by antibodies to non-myelin antigens. Non-myelin antibodies 
present in MS patients target neuronal surface molecules (axolemma-enriched fractions, 
neurofascin, gangliosides), cytoskeletal proteins (neurofilaments (NF), neurofilament 
light chain NF-L), intracellular enzymes, signaling molecules and chaperones (ß-arrestin, 
retinal arrestin, heat shock proteins, glutamate decarboxylase, proteasomes) and nuclear 
antigens (nuclear ribonuclear proteins).111 These antibodies present a different 
mechanism of immune-mediated axonal injury.  For example, antibodies to neurofascin 
(NF-186, NF-155), which is a cell adhesion molecule involved in axon subcellular 
targeting and synapse formation during neural development, caused exacerbation of EAE 
without demyelination in the spinal cord of rats. When anti-neurofascin antibodies were 
co-transfected with MOG specific T-cells, they selectively targeted Nodes of Ranvier and 
inhibited neurotransmission in an MS animal model.112   In separate experiments, chronic 
progressive MS patients had significantly higher levels of NF-L specific antibodies in 
sera compared to that of patients with other neurological diseases.113,114 How the anti-NF 
and anti-NF-L antibodies arise and what their specific effects are on the axon is unclear, 
but their correlation with disease progression appears applicable in a biomarker specific 
manner.112-114  
 
 In addition, antibodies to hnRNP A1, B2 (hnRNP A1/B2) were present in CSF of 
MS and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) 
patients, but not in normal controls.12,92-94,97,98,115  hnRNPs are RNA-binding proteins that 
play a major role in adjustment of pre-mRNA splicing through various factors.116 They 
also participate in mRNA stability, NF-k-ß dependent transcription and telomerase 
activity.117-119   hnRNP A1 plays several key roles in neuronal functioning and its 
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depletion, either due to debilitated cholinergic neurotransmission or causing drastic 
changes in RNA metabolism during autoimmune reactions.12,120 Recently, RNA binding 
proteins have gained attention because a large number of these proteins were mutated in 
neurodegenerative diseases.121,122  RNA binding proteins use protein aggregation as part 
of a normal regulated, physiological mechanism that controls protein synthesis.  The 
process of regulated protein aggregation is most evident in the formation of stress 
granules (SG).123  HnRNPA1 has been shown to relocate into cytoplasmic SG in the 
presence of stress stimuli, such as osmotic shock or OS.124 Further, studies showed that 
addition of antibodies to hnRNPA1 affected its distribution from a primarily nuclear 
location to a mixed nuclear/cytoplasmic distribution.12,95,125 It was known that anti-
hnRNP A1 antibodies decreased neuronal firing in vitro but it wasn’t clear if the 
antibodies to this intracellular protein could penetrate neurons and find its target.94 
Recent studies revealed that anti-hnRNP A1 antibodies penetrated neuronal cells via 
clathrin mediated endocytosis and caused deleterious effects to the neurons.12,94,95,125 
Specifically, anti-hnRNP A1 antibodies increased apoptosis, reduced ATP levels, and 
caused redistribution of endogenous hnRNPA1 protein. Thus, anti-hnRNP A1 antibodies 
altered endogenous protein localization as well as inhibited normal cellular processes in 
vitro.   
 
 The presence in MS patients of two types of autoantibodies may not be mutually 
exclusive.  It is possible that antibodies to myelin antigens may have an impact on the 
early, relapsing stages of disease while the non-myelin antigens play a more dominant 
role in progressive stages of MS.  More importantly, both types of antibodies may cause 
neurodegeneration through activation of apoptotic, inflammatory cytokine, and immune 
response pathways. 
 
 
hnRNP A1 and M9 Antibodies 
 
 hnRNP A1 is an RNA binding protein overexpressed in neurons.  hnRNP A1 is a 
member of a family of over 20 nuclear proteins designated as heterogeneous nuclear 
ribonucleoproteins (hnRNPs).126  The hnRNPs are involved in pre-MRNA processing 
events as well as transport of mRNAs to the cytoplasm for translation in eukaryotic 
cells.126 While some hnRNPs are strictly nuclear molecules, a subset of hnRNPs, 
including hnRNP A1 shuttle constantly between the nucleus and the cytoplasm.126  
hnRNP A1 functions in pre-mRNA packaging, splicing, mRNA metabolism and  
transport.126,127  hnRNP A1 is a 320 amino acid protein with many functional motifs.127 
The N-terminus of hnRNP A1 consists of 185 residues which can be divided into two 90 
amino acid repeats which function as RNA recognition motifs (RRM) or RNA binding 
domains (RBD).127 Within each RBD are two consensus binding sequences termed RNP1 
and RNP2 which are part of the binding surface of the RBD.127 The remaining 135 amino 
acid C terminal region contains additional functional motifs.  The C-terminal region is 
rich in glycines and contains an RGG box region that is involved in RNA binding, 
protein-protein interactions, nuclear localization, and RNA strand annealing activity.127 
Near the end of the C-terminus of hnRNP A1 is the M9 sequence encompassing amino 
acids 268-305.  M9 serves as both a nuclear export sequence and nuclear localization 
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sequence (NES/NLS) for hnRNP A1, thus making this region responsible for the 
nuclear/cytoplasmic shuttling of the hnRNP A1 protein.126,128 The final motif on the C-
terminus of hnRNP A1 is termed the ‘F peptide’.  The F peptide spans the region from 
amino acids 301-319 and must be phosphorylated to initiate the binding of hnRNP A1 to 
transportin 1 (Trn1) which is necessary for cellular trafficking between the nucleus and 
cytoplasm.129 
 
 Mechanisms involving RNA metabolism, and in particular RBPs, are becoming 
increasingly important in the pathogenesis of neurodegenerative disorders such as 
frontotemporal dementia, multisystem proetinopathy, and amyotrophic lateral sclerosis 
(ALS).130-132  Importantly, MS patients have been shown to develop autoantibodies to the 
RBP hnRNP A1.11,12,92,94,95,97,98,125  Epitope analyses has shown that the antibody 
response in MS patients is specific for the ‘M9’ region of hnRNP A1.  M9 is hnRNP 
A1’s nuclear export sequence/nuclear localization sequence (NES/NLS) which is 
required for hnRNP A1’s transport into and out of the nucleus.12,92-95,97,98,125,126  Previous 
studies have shown that anti-hnRNP A1-M9 antibodies transfected into neuronal cells 
cause neurodegeneration and alter the RNA expression of the spinal paraplegia genes 
(SPG4 (spastin), SPG7 (paraplegin), and SPG20 (spartin)).12,125,126  Mutations in the 
SPGs (of which spastin is the most common) result in hereditary spastic paraparesis 
(HSP), which is clinically indistinguishable from progressive MS.12,126,133  It appears 
there may be a potential link between anti-hnRNP A1, M9 specific antibodies, produced 
in MS patients and the alterations in the SPGs expression levels which could be a 
possible contributing factor to the neurodegeneration seen in MS. 
 
 
Apoptosis 
 
 Apoptosis is the term utilized to describe the process of programmed cellular 
death.134 Apoptosis is a vital component of numerous cellular processes including 
development and function of the immune system, cell turnover, embryonic development, 
and naturally induced cellular death by humoral and chemical systems within the body.134 
During development and aging, apoptosis occurs normally within the body as a 
homeostatic mechanism in order to maintain tissues and cell populations.134 Through a 
protective manner apoptosis can act as an immune response by causing cell death in cells 
that have been attacked by a toxic foreign agent.134   
 
 There are two main pathways leading to apoptosis: the extrinsic “death receptor” 
and intrinsic or “mitochondrial” pathway.134 Although once thought to be completely 
separate pathways, evidence now suggests that molecules in one pathway can have effect 
on the other pathway.134 A third pathway has emerged involving apoptosis induced by 
cytotoxic T-cells through what is now called the perforin/granzyme pathway.134  
Although each pathway is initiated in a different fashion, each pathway shares the same 
executioner caspase, caspase 3.134 The executioner pathway is initiated by the cleavage of 
caspase 3.134  The action of caspase 3 cleavage results in DNA fragmentation, nuclear and 
cytoskeletal protein degradation, apoptotic body formation, protein cross-linking, 
phagocytic cell receptor expression, and ultimately phagocytosis of the cell.134 Two of the 
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main mechanisms used to determine apoptotic events within studies is to measure the 
ATP levels and cleaved caspase 3 levels of cells. 
 
 
Endosomes/ Clathrin and Caveolar Mediated Endocytosis 
 
 Endocytosis is the invagination of the plasma membrane and the formation of 
vesicles and vacuoles through membrane fusion which internalizes fluid, solutes, 
macromolecules, and other cellular components.135 The two main types of endocytosis 
are clathrin-mediated endocytosis and caveolar-mediated endocytosis.135  Caveolar 
uptake is performed by non-coated plasma membrane invaginantions called caveolae.136  
Caveolae are notably known for their association with caveolins which are a family of 
cholesterol-binding proteins.136  Caveolins are responsible for maintaining the structure 
of the endosomes formed during caveolar-mediated endocytosis.136 Notably, many of the 
molecules within caveolae are also present within lipid rafts.136 Clathrin-mediated 
endocytosis takes place when specific molecules are taken up into clathrin coated 
invaginations for transport within the cell.137 The adaptor complex AP2 is a multimeric 
protein on the plasma membrane responsible for internalizing molecules into the clathrin-
coated vesicles for transport.137 Once selective cargoes are packaged within the clathrin 
vesicles, these transport vesicles fuse with early endosomes for transport.137 Depending 
on cargo being assessed, molecules can be transported by one or both of these two 
pathways. 
 
 Within neurons, endosomes play a vital role in maintaining viability of the cell 
due to their role in transporting various molecules throughout the axon.  It has been 
widely accepted that signaling endosomes are the transport mechanism utilized by these 
essential molecules for transport anterogradely as well as retrogradely along microtubules 
in the axon.138  The motors responsible for axonal transport along microtubules are 
dyneins and kinesins.138  Dynein motors are responsible for retrograde transport while 
kinesins are the anterograde motors.138  Both kinesin and dynein motors transport long 
range signals along the axon between the soma (cell body) and the axon terminals.138  
One example of retrograde signaling can be seen through the internalization of Trk 
receptors via clathrin-mediated endocytosis into signaling endosomes at the distal axon.  
These internalized Trk receptors are then retrogradely transported to the soma in order to 
initiate survival responses.138  Another example of signaling endosomes can be visualized 
through the transport of La, an RBP.  La protein is an RBP that is anterogradely 
transported along microtubules via kinesin motors.138 When La reaches its destination at 
the axon terminal it is covalently modified by small ubiquitin-like modifying 
polypeptides (SUMO).138 Once ‘sumoylated’, La is then able to bind dynein motors and 
transport retrogradely back to the soma, thus finishing its transport cycle.138   
Studies have shown that the disruption of retrograde transport leads to a variety of 
neurodegenerative disorders.138 Diseases such as hereditary spastic paraplegia (HSP) and 
ALS are characterized by “dying back” of axons in which the axon degeneration shows a 
distal to proximal progression.138 Specifically, the disruption of dynein motor function 
has been shown to cause neurodegeneration in both mouse and human diseases.138 
However, it also appears that anterograde transport could in theory have an effect on 
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neurodegeneration.  It has been shown that disruption of retrograde or anterograde 
transport can cause a blockage of trafficking in both directions due to a resulting “traffic 
jam”.138 This traffic jam, which can be caused by disruption of either transport 
mechanism results in the impaired transport of signaling endosomes.138 
 
 
RNA Granules 
 
 Neurons are required to communicate over long distances in a bidirectional 
manner.  This bidirectional communication system utilizes macromolecules encoded with 
essential information which link synapses, dendrites, axons, and the soma.139  
Bidirectional transport is composed of two different transport systems, anterograde and 
retrograde transport.  Anterogradely, messenger RNA (mRNA) is transported from the 
soma to the terminals of the axon.  The mRNA is locally translated at the terminals.  This 
new translated protein is then shipped back to the soma by retrograde transport.  
Anterograde and retrograde transport use slightly different mechanisms of action.  
Anterograde transport occurs due to the transport of RNA granules with the use of 
kinesins as the motor to transport the molecules anterogradely down microtubules toward 
the axon terminals until they reach sites of translation prior to reaching axon terminals in 
most instances.139 Retrograde transport uses signaling endosomes as well as importins 
and dynein to transport molecules retrogradely along microtubules from axon terminals 
back to the soma.139 Signaling endosomes are the results of neutrophins (neuronal growth 
factors) being released from target tissues and binding to Trk receptors. This binding 
action forms a ligand- receptor complex, which is internalized forming a signaling 
endosome.  Importins and dynein are proteins that act as the motor during retrograde 
transport.  When importins and dynein are bound directly by molecules such as signaling 
endosomes, the importins and dynein act as a motor by trafficking the bound molecule in 
a retrograde fashion along the microtubule network towards the soma.139 
 
 RNA granules also known as neuronal granules are utilized in anterograde 
transport and consist of RNA binding proteins, mRNAs, ribosomal machinery for 
translation of mRNA, and microtubule motors.140  RNA granules (neuronal granules) are 
utilized to transport mRNA in an anterograde manner along the microtubules for 
localized translation likely near the axon terminals.140,141  It is suggested that there may 
be multiple types of RNA granules due to a lack of complete co-localization of various 
proteins and RNA granule markers.140 Additionally, the mechanism by which ribosomal 
subunits within the RNA granules are repressed from translating mRNAs within the 
granules is not clearly understood.  However, it is hypothesized that something within the 
RNA granules, such as micro-RNAs may act to block the ribosomal subunits by blocking 
mRNA elongation at the polysome stage.140      
 
 In addition to the role RNA granules play in neuronal trafficking under normal 
conditions, they also play a very important role in neurons during stress.  In response to 
stress stimuli, RNA granules form two main types of stress induced granules known as 
Processing bodies (P bodies) and stress granules.124  P bodies are RNA granules whose 
internal mRNA cargo is tagged for degradation.124,141 Stress granules are RNA granules, 
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which form during nutrient deprivation or metabolic stress and contain mRNA cargo that 
is stored in an abortive transition initiation complex enabling them to enter rapid 
reinitiation once stress stimuli are gone.124   
 
 RNA binding proteins (RBPs), which bind and transport mRNA , are responsible 
for the recruitment of themselves as well as their bound cargo to RNA granules.  There 
are several RBPs present within RNA granules.  Each RBP contains a LC region (low 
complexity polypeptide sequence) within the RBPs with little diversity in their amino 
acid composition.141 The LC region is composed of many tyrosine residues and is 
responsible for the localization of the RBP-mRNA complex to RNA granules.  hnRNP 
A1 is one of the RBPs found within RNA granules during the stress response.124,140,141  
hnRNP A1 binds various mRNAs for transport and translation within neurons.  hnRNP 
A1 contains an LC region between amino acids 186-320 which includes the M9 region 
(268-305) and the F peptide (305-320).141 During stress, a stretch of serines located in the 
F peptide is phosphorylated by Mnk 1/2 kinase.124 The phosphorylation of the F peptide 
results in a redistribution of hnRNP A1 to the cytoplasm by abrogating hnRNP A1 and 
TNPO1 interactions.124 hnRNP A1 and its bound mRNA cargo localize to stress granules 
but are not found within P bodies during the stress response.124 The action of hnRNP A1 
binding to stress granules rather than P bodies, provides hnRNP A1 and its bound mRNA 
cargo a harbor of safety until the stress response has been abolished at which point 
hnRNP A1 is released from the protective stress granules where it can continue 
trafficking its mRNA cargoes.  Interestingly, hnRNP A1 binding to poly(A) mRNA 
increases during the presence of stress whereas its binding to TNF- mRNA decreases 
during the presence of stress.124 It appears that hnRNP A1 shows a preference to protect 
poly(A) mRNA over TNF- mRNA during stress.   
 
 
Experimental Autoimmune Encephalomyelitis (EAE) 
 
 EAE is a mouse model of CNS autoimmune disease mediated by CD4+ T-cells.142 
The disease is exemplified by demyelination of axons caused by perivascular CD4+ T-
cells and mononuclear infiltration leading to hind-limb paralysis.142,143 Serving as the best 
animal model to date for MS, EAE mice are shown to have similar disease course and 
features as MS patients such as inflammation, demyelination, axonal loss, and gliosis.143 
EAE provides a relevant model to study the immune response as well as axonal damage 
in the immune-mediated demyelinating disorder MS.142,143 There are two methods of 
EAE disease induction: the active induction and adoptive transfer model.142 Both 
methods can be used in female SJL or C57Bl/6 mice, however the disease course 
between the two strains varies slightly.  SJL mice tend to produce a relapsing-remitting 
disease course, whereas the C57/Bl6 mice produce a more chronic and continuous 
disease.143 
 
 The active induction method is often termed the “classic” EAE model.  This 
model is induced by immunization with myelin peptides such as proteolipid protein 
(PLP), myelin oligodendrocyte glycoprotein (MOG), or myelin basic protein (MBP) in 
complete Freund’s adjuvant (CFA).142,143 The immunization is performed concurrently 
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with pertussis toxin injection to disrupt the blood-brain barrier BBB.  In the active 
induction model, the myelin peptide of choice often depends on mouse strain and 
symptomology desired.  SJL mice are regularly immunized with PLP and demonstrate a 
relapsing-remitting disease course.143  C57Bl/6 mice are generally immunized with MOG 
and display a more chronic, “smoldering” disease course.143  The disease onset generally 
occurs within 9-12 days post immunization and disease course varies as mentioned 
previously.143 
 
 The passive or “adoptive transfer” model utilizes passive transfer of 
encephalogenic CD4+ T-cells into recipient mice.142,143 In this model, donor mice are 
initially immunized as in the active induction model, however, these donor mice are not 
injected with pertussis toxin.142 Approximately 10 days following immunization of donor 
mice, spleens and lymph nodes are extracted and T-cells are cultured for 3-5 days in 
media containing a milieu of cytokines to produce encephalogenic CD4+ T-cells.142 
Following culture of the “activated” T cells, recipient mice are injected with the 
encephalogenic CD4+ T-cells by either i.p or i.v. to induce disease.  The adoptive transfer 
model can also be induced in either SJL or C57Bl/6 mice with slightly different disease 
course similar to that described in the active induction model.142  The disease course of 
adoptive transfer model mice is overall generally more severe than the disease course of 
active transfer model mice.142  The adoptive transfer model mice generally display 
symptoms within 6-10 days post transfer. 
 
 Clinical scoring of EAE is based on a scale from 0-5 to most accurately mimic the 
human disease based on the symptoms exhibited by mice.  The basic scoring system is as 
follows: 0- normal mouse with no disease symptoms; 1- limp tail or hind limb weakness, 
but not both; 2- limp tail and hind limb weakness; 3- partial hind limb paralysis; 4- 
complete hind limb paralysis; 5- moribund state, death.142  Within the scoring system 
there are also 0.5 increments based on certain visualized occurrences that would place the 
animal between scoring levels.    
 
 
Antibody Augmented EAE 
 
 Within the world of autoimmune disorders, autoantibodies to specific antigens 
have been implicated to show specificity to certain disorders.  For example, patients with 
MS and HAM/TSP have been shown to produce autoantibodies to the M9 epitope of the 
protein hnRNP A1.11,12,92-95,97,98,125  Other autoimmune disorders have also implicated 
various autoantibodies specific to certain diseases.  Anti-recoverin antibodies were found 
to be present in patients with cancer associated retinopathy (CAR).144  Interestingly it was 
discovered that anti-recoverin antibodies lead to apoptosis of retinal cells in CAR.144  In 
patients with neuromyelitis optica (NMO), patients produce antibodies to aquaporin-
4.19,145  Bennett et al. demonstrated that six different recombinant antibodies produced 
which were specific to aquaporin-4 epitopes contributed to CNS pathology in Lewis rats 
with EAE.146 Furthermore, Bradl et al. treated EAE Lewis rats with IgG isolated from 
both antibody-positive and antibody negative NMO patients.  Bradl et al. provide 
evidence that while antibody-negative patient IgG have little effect to augment disease, 
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antibody-positive IgG from NMO patients worsen disease and induce NMO-like lesions 
in Lewis rats with EAE.145  
 
 
Objectives and Specific Aims 
 
 
Objectives 
 
 At the onset of my project, it was previously shown that patients with MS 
produced autoantibodies against the RBP hnRNP A1.  Data at this point also 
demonstrated that the autoantibodies contained epitope specificity to hnRNP A1-‘M9’ 
(hnRNPA1’s NES/NLS).  Additionally, it had been shown that anti-M9 specific 
antibodies decreased neuronal firing in patch-clamp experiments and caused 
neurodegeneration in a neuronal cell line.   
 
 My project was designed to further determine the effect of anti-M9 antibodies on 
neuronal cells both in vivo and in vitro.  My project objectives included determining 
mechanisms of antibody entry into neuronal cells, anti-M9 effects on cellular viability, 
neuronal protein expression and RNA levels, and to determine antibody effect upon the in 
vivo EAE murine model of MS.  Additionally, my project included aims to further the 
understanding of mRNA binding partners of hnRNP A1 as well as determine whether 
anti-M9 antibodies have an effect on hnRNP A1 and RNA granules during cellular stress.  
 
 
Specific Aim 1 
 
 Describe anti-hnRNPA1 antibodies penetration and the deleterious effects they 
have on neuronal cells in vitro. 
 
 
Specific Aim 2 
 
 Analyze whether a hnRNP A1 protein - spastin mRNA interaction exists as well 
as determine whether anti-hnRNP A1-M9 antibodies possess the ability to interact with 
RNA granules. 
 
 
Specific Aim 3 
 
 Determine the effects of anti-hnRNP A1-M9 antibodies on the clinical phenotype 
and cellular mechanisms of neurodegeneration in the CNS of mice with EAE. 
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
Aim 1 Methods 
 
 
Cells 
 
 SK-N-SH cells (ATCC, HTB-11), an immortalized human neuroblastoma cell 
line was maintained in Dulbecco’s modified Eagle’s medium (DMEM) with F12, 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin antibiotics. 
 
 
Antibodies 
 
 Anti-hnRNP A1 antibodies specific to the M9 epitope of hnRNP A1 were 
obtained from Abcam (ab 4791-rabbit polyclonal, ab 5832- mouse monoclonal) and 
rabbit IgG were obtained from Abcam (ab 107866 ) and Millipore ( 12-370). Anti-
clathrin antibodies were purchased from Novus Biologicals (NBP1-05991).    
 
 
Atto550 NHS Labeling of Anti-hnRNP A1 and Normal IgG Antibodies 
 
 A 0.1M NaHCO3 buffer was made (8.4g NaHCO3, 22.9g NaCl, 1 liter H2O) and 
brought to a pH of 8.4 with the following solution: 10.6g Na2CO3, 29.2g NaCl, 1 liter 
H2O.  35 μg of antibodies (1μg/ml) were added to 70μl of Atto550 NHS Ester (Sigma-
Aldrich, 92835) and 500μl of NaHCO3 buffer.  The mixture was rotated for 1 hour at 
room temperature.  After the hour-long incubation, the mixture was injected into Slide-a-
lyzer dialysis cassette (ThermoFisher Scientific) and dialyzed overnight in PBS.  The 
next day the labeled antibodies were concentrated by centrifugation in Amicon filters 
(Millipore) and concentration was determined with a NanoDrop 1000 spectrophotometer 
(ThermoFisher Scientific). 
 
 
Antibody Penetration Tracing 
 
 150,000 SK-N-SH cells were seeded per chamber into four chamber slides.  
Atto550 labeled anti-hnRNP A1 and rabbit IgG were added at a concentration of 2μg/ml 
directly into DMEM.  An untouched control cell group was employed as a negative 
control.  At 24 and 72 hours after antibody and IgG addition, cells were fixed with 4% 
paraformaldehyde for 15 minutes at room temperature.  Cells were then washed 4 times 5 
min each with PBS, mounted, and imaged using a Zeiss Axio Observer A1 fluorescent 
microscope (Carl Zeiss).  Quantification of antibody penetration percentage between the 
anti-hnRNP A1 treated and control rabbit IgG treated cells was performed using 
AxioVision Software.  Five representative images were used per treatment from the 24 
hour images.  Antibody penetrated cells were divided by the total number of cells to give 
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a percentage of antibody penetration: Cells with antibodies per image/Total cells per 
image) x 100 = Penetration Percentage). 
 
 
Anti-hnRNP A1 and Early Endosomes Co-localization 
 
 100,000 SK-N-SH cells per chamber were seeded into 8 chamber slides.  Atto550 
labeled antibodies were added directly into DMEM/F12 at a concentration of 2μg/ml.  At 
24 hours prior to antibody addition, 20μl of Cell Light Early Endosome GFP (Invitrogen) 
was added to label endosomes.  At 6, 24, and 48 hours after antibody addition, cells were 
fixed with 4% paraformaldehyde for 15 minutes at room temperature.  Cells were then 
washed, mounted, and observed as described above.  Quantification of the endosome 
penetration for the three time points was performed in AxioVision Software Version 4.8.  
Total colocalization events per cell was determined for 5 representative cells at the 6 hr., 
24 hr, and 48 hr. time points respectively. 
 
 
Determination of Clathrin or Caveolar Mediated Endocytosis 
 
 2.5 million SK-N-SH cells were seeded into 35mm glass-bottom dishes (MatTek 
Corp).  Three plates each were designated as clathrin or caveolar mediated endocytosis.  
Pitstop 2 reagent (Cellagen tech, C7487-25) was added at a 10nM concentration for 30 
minutes into DMEM/F12 media to block clathrin mediated endocytosis.  Nystatin 
(24µl/mL) solution (Sigma-Aldrich, N1638) was added into three separate dishes for 30 
minutes to block caveolar mediated endocytosis.  After the 30-minute incubation, anti-
hnRNP A1 and IgG antibodies were added at a concentration of 4μg/mL.  Live imaging 
of the cells was performed at 6, 12, and 24 hours after antibody addition in order to 
determine antibody penetration.  Co-immunoprecipitations were performed in order to 
confirm the clathrin pathway as the method of penetration.  Protein A beads were blocked 
with 6% Milk-TBS for an hour at room temperature.  Beads were then washed 4 x 5 
minutes with IP buffer.  Anti-hnRNP A1 antibodies and control rabbit IgG were attached 
to protein A beads overnight at 4C.  Beads were then washed 4 x 5 min with IP buffer.  
SK-N-SH cell lysate was added over beads without antibodies, hnRNP A1 antibody 
beads, and control IgG beads overnight at 4C.  Beads were washed 4 x 5 minutes with IP 
buffer. Beads were spun down 5 minutes at 5000 rpm.  50µl of 2x buffer was added per 
tube and heated 5 minutes at 95C.  Tubes were then cooled while spinning 5000rpm for 5 
min at 4C.  150µg of each sample was loaded onto a 10% Tris gel and run at 100V for 90 
minutes.  The gel was then transferred to a PVDF membrane at 100V for 90 minutes.  
The membrane was blocked for 30 minutes at room temperature with 6% milk-TBS.  
Membranes were then washed 4 x 5 minutes with TBS-T.  Anti-clathrin interactor-1 
antibodies (NBP1-05991) were added at a concentration of 1:2000 in 6% milk-TBS 
overnight at 4C.  The membrane was then washed 4 x 5 minutes in TBS-T.  Secondary 
anti-rabbit HRP antibodies were added for 50 minutes at room temperature at a 
concentration of 1:10000.  The membrane was then washed 4 x 5 minutes.  SuperSignal 
West Pico Chemiluminescent Substrate (ThermoFisher Scientific) was then added for 5 
minutes and the membrane was immediately imaged.     
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Measurement of ATP Levels 
 
 ATP levels were determined using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega) which quantitates the ATP levels based upon luminescence signal 
production which is equivalent to total ATP present.  The CellTiter-Glo system utilizes a 
luciferin based assay which in the presence of ATP converts luciferin to oxyluciferin, 
resulting in the production of a luminescent signal.  The intensity of the luminescence 
(RLU=Relative Luminescent Units) is directly proportional to the amount of ATP within 
the system. 50,000 SK-N-SH cells were seeded per well into a 96 well plate.  Anti-
hnRNP A1 antibodies produced in rabbit and normal rabbit IgGs were added at a 
concentration of 8μg/ml directly into 100μl of DMEM/F12 media.  An untouched control 
cell group also served as a control.  At 48 and 72-hour points after antibody addition 
100μL of CellTiter-Glo Reagent (Promega) was added.  After one hour of incubation, the 
plate was read on a spectrophotometer between wavelengths 560Ex/590Em. 
 
 
Determination of Antibodies Effect on Caspase 3/7 Levels 
 
 50,000 SK-N-SH cells were seeded per well into a 96 well plate.  Anti-hnRNP A1 
antibodies and normal rabbit IgGs were added at a concentration of 8μg/ml and an 
untouched control cell group served as an additional control.  At 24, 48, and 72 hours 
after antibody addition 100μl of ApoOne Homogenous Caspase 3/7 reagent (Promega) 
was added per well.  After one hour of incubation the plate was read on a 
spectrophotometer at 485Ex/530Em wavelengths.  
 
 
Measurement of Cytotoxicity 
 
 Cytotoxicity was determined using the Cytotox-ONE Cytotoxicity Assay 
(Promega).  Cytotox-ONE Cytotoxicity Assay determines cytotoxicity of the cell by 
determining membrane permeability by measuring the release of lactase dehydrogenase 
(LDH) from the cell.  This is measured by the LDH dependent conversion of resazurin 
into the fluorescent resarufin product.  The amount of cytotoxicity is measured as relative 
fluorescent units (RFU). 100,000 SK-N-SH cells were seeded per well in triplicates into a 
96 well plate.  Anti-hnRNPA1 antibodies and normal rabbit IgGs were added at a 
concentration of 8µg/ml and an untouched control cell group served as normal 
cytotoxicity percent control and a group with only culture media served as a background 
control.  At 24, 48, and 72 hours the plate was taken out of the incubator and lysis 
solution (Promega) was added for 30 minutes at room temperature.  Cytotox-ONE 
reagent was then added to all chambers and let to sit at room temperature for 10 minutes.  
Stop solution was then added to all chambers and readings were taken with a 
spectrophotometer at wavelengths 560Ex/590Em.  To determine cytotoxicity the 
following equation was used [(Experimental group fluorescence – Background 
fluorescence from media group) / (Control cell group fluorescence – Background 
fluorescence from media group)] x 100.  
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Double Labeling to Image Redistribution of Endogenous hnRNP A1 
 
 2.5 million SK-N-SH cells were seeded into 35mm MatTek dishes with a glass 
coverslip bottom.  Normal rabbit IgG and rabbit produced anti-hnRNP A1 antibodies 
were added into DMEM/F12 media at a concentration of 4μg/mL.  24 hours after 
antibody addition, cells were fixed for 15 minutes with 4% paraformaldehyde.  Cells 
were then blocked and permeablized for 30 minutes with 6% Milk-PBS + 0.4% Triton.  
Cells were then washed 4 x 5min with PBS.  Mouse monoclonal hnRNP A1 antibodies 
specific to the M9 epitope of hnRNP A1 were added at a dilution factor of 1:1000 for 1 
hour at room temperature in PBS to label endogenous hnRNP A1.  Cells were washed 4 x 
5min with PBS.  Anti-mouse Fluorescein labeled secondary antibody was added at 
1:1000 for 50 min at RT in PBS.  Cells were then washed and imaged in PBS.  
Quantification of endogenous hnRNP A1 redistribution was performed by comparing the 
densitometric mean of the FITC fluorescence expression of the nucleus vs. the cytoplasm 
of 10 cells per group using AxioVision Software. 
 
 
Statistics 
 
 Statistical analyses were performed in GraphPad Prism software using either 
student t-test or one-or two-way ANOVA. Significant differences depicted as standard 
error measurement *<0.05, **<0.01, ***<0.001, ns=not significant. 
 
 
Aim 2 Methods 
 
 
Cells 
 
 SK-N-SH cell line (ATCC, HTB-11), an immortalized human neuroblastoma cell 
line was maintained in Dulbecco’s modified Eagle’s medium/F12 supplemented with 
10% fetal bovine serum and 1% penicillin-streptomycin antibiotics.  100mm plates were 
seeded for the RNA immunoprecipitation, Real Time PCR analysis, and Western 
blotting.  105 SK-N-SH cells were seeded per well into 500uL of complete DMEM/F12 
media into 8 well chamber slides (Corning #354632) for RNA granule 
immunocytochemistry experiments. 
 
 
Exposure of SK-N-SH Cells to Antibodies in vitro 
 
 Anti-hnRNP A1 antibodies were obtained from Abcam (ab4791-rabbit 
polyclonal, ab5832 - mouse monoclonal) and Millipore (05-1521- mouse monoclonal; 
04-1469 – mouse monoclonal). The anti-hnRNP A1 antibodies are specific for hnRNP 
A1-M9 and have been shown to overlap the M9 immunodominant epitope recognized by 
IgG isolated from MS patients 12. Isotype-matched anti-rabbit IgGs were obtained from 
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Abcam (ab107866) and Millipore (12-370).  Antibodies were added to the culture media 
of SK-N-SH cells at a concentration of 8ug/ml for each assay as determined in previous 
studies 1.  Primary antibodies utilized for protein detection by Western blot were as 
follows: spastin (SPG4-Abcam ab38150), paraplegin (SPG7-Abcam ab154989), spartin 
(SPG20-Abcam ab94950), and hnRNP A1-(Millipore 05-1521).  Antibodies were used at 
manufacturers recommended concentration.  Antibodies utilized for immunochemistry 
were as follows: TAR-DNA Binding Protein (TDP-43 (Millipore MABN45)), GW-182 
(Abcam ab70522), or hnRNP A2/B1 (Abcam ab6102). 
 
 
RNA Immunoprecipitation 
 
 SK-N-SH cells were cultured in 100mm cell culture dishes.  Cells were scraped 
and lysate extracted.  Lysate was added to protein A/G beads labeled with either anti-
hnRNP A1 antibody (ab4791) or anti-IgG (Millipore 12-370) as a control for non-specific 
binding.  Samples were rotated overnight at 40C.  The following day, bound proteins 
were eluted from the protein A/G beads.  Eluent from both samples as well as control 
SK-N-SH lysate was run on SDS gels and probed for hnRNP A1 to confirm specific 
binding of hnRNP A1 protein.  RNA was then extracted from the eluents.  RNA 
concentration and quality was determined by 260/230 ratio by Nanodrop (ThermoFisher 
Nanodrop 1000).  RNA was used as a template for first strand synthesis to make cDNA 
by a High Capacity cDNA Reverse Transcription kit (Applied Biosystems 4368814) 
using a thermocycler.  cDNA concentration and quality was determined by Nanodrop.  
cDNA was used to perform quantitative real-time PCR probing for potential RNA 
binding partners to hnRNP A1 protein. 
 
 
Determination of Protein Levels of Antibody Treated SK-N-SH Cells by Western 
Blot 
 
 SK-N-SH cells seeded in 100mm dishes were treated with either anti-hnRNP A1 
antibodies, anti-IgG antibodies, or were left untreated.  Antibody treatments were at a 
concentration of 8 ug/ml in DMEM/F12 complete media for 48 hours.  Following 
antibody treatment, cells were scraped and lysates were centrifuged 5 min @2500 rpm.  
Supernatants were heated with 2x running buffer for 5 minutes @ 95C and then samples 
were loaded onto 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and run at 100V for 1.5 hours.  Gels were then transferred onto nitrocellulose 
membranes at 100V for 1.5 hours.  Membranes were blocked with 6% milk-TBS for 40 
minutes at room temperature.  Primary antibodies were then added overnight at 4C at 
manufacturer’s suggested concentration.  Primary antibodies were as follows: SPG4 - 
Abcam ab38150, SPG7 – Abcam ab154989, SPG20 – Abcam ab94950, and hnRNP A1 
(Millipore 05-1521). The next day, membranes were washed 4 x 5 min with TBS.  
Secondary anti-HRP antibodies were then added for 50 minutes at room temperature 
at1:10000 dilutions.  Membranes were washed 4x5 minutes with TBS-Tween.  
Membranes were then developed and imaged. 
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Immunocytochemistry of hnRNP A1-M9 Antibody Colocalization with Neuronal 
Granules 
 
 105 SK-N-SH cells were seeded per well into 500uL of complete DMEM/F12 
media into 8 well chamber slides (Corning #354632).  Anti-hnRNP A1 and control IgG 
antibodies were labeled with Alexafluor 488 and added to the culture media of SK-N-SH 
cells at a concentration of 8 ug/ml for each assay as determined in previous studies 1.  48 
hours following antibody addition, cells were fixed with 4% paraformaldehyde for 30 
minutes at room temperature.  Fixed cells were then blocked and permeabilized with 6% 
Milk-PBS + 0.4% TritonX-100.  Cells were then labeled for TDP-43 (stress granules), 
GW-182 (P bodies), or hnRNP A2/B1 (transport granules) at the manufacturer’s 
suggested concentration overnight at 4C.  Following primary antibody incubation, cells 
were washed 4 x 5 minutes with PBS.  Cells were treated with secondary anti-mouse Cy3 
at manufacturer’s suggested concentration for 2 hours at room temperature.  Cells were 
washed 4 x 5 minutes with PBS, mounted with DAPI mounting medium, and imaged.  
Colocalization events were quantified based on average number of colocalizations.  
Colocalization events were counted and compared to number of cells in each image 
resulting in a ratio of colocalization events to total number of cells. Approximately 500 
cells were counted per group. Data was analyzed by one-tail t-test based on previously 
observed trend 1.  (P values *≤0.05; **≤0.01; ***≤0.001). 
 
 
Aim 3 Methods 
 
 
Animals 
 
 C57BL/6J female mice were purchased from Jackson Laboratories (Bar Harbor, 
ME).  Mice were 11 weeks of age at experimental onset and were housed on a 12:12 hour 
light:dark cycle, with standard chow and water freely available. All animal procedures 
were reviewed and approved by the University of Tennessee and Veterans Affairs 
Medical Center – Memphis Institutional Animal Care and Use Committees. 
 
 
Induction of Experimental Autoimmune Encephalomyelitis/Antibody Injections 
 
 On day 0, mice were immunized with 150 ng of pertussis toxin via intraperitoneal 
(ip.) injection and 200 ul of myelin oligodendrocyte glycoprotein (MOG)35-55/complete 
Freund’s adjuvant (CFA) emulsion subcutaneously (100 ul between the shoulders and 
hips).  The following day (day 1), each mouse was injected with an additional 150 ng of 
pertussis toxin. Pertussis toxin and MOG35-55/CFA were obtained from Hooke 
Laboratories (cat no. EK-2110) (Lawrence, MA).  Mice were checked daily for clinical 
signs of EAE (see clinical scoring section below).  Upon first clinical signs, mice were 
injected ip. with either phosphate buffered saline (PBS), mouse IgG2b (isotype control) 
(Millipore MABC006), or mouse anti-hnRNP A1-M9 (Millipore 04-1469), whose 
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epitope overlaps with the immunodominant epitope of IgG isolated from MS patients.  
Each animal received three injections of 100 ug of antibody per injection every other day 
from the initial signs of EAE. 
 
 
Clinical Scoring 
 
 Clinical scoring was adapted from “Appendix A: Mouse EAE Scoring Guide” 
found in the protocol of the Active Induction EAE Kit from Hooke Laboratories (Hooke 
cat no. EK-2110). The scoring system is composed of scoring values ranging from 0-5.0 
increasing at increments of 0.5.  A score of 1.0 serves as the initial sign of disease onset 
and is scored as an observation of a ‘limp tail’, whereas 5.0 is moribund.  Mice with 
scores of 4.0 or higher for more than two days are euthanized and given a score of 5.0 for 
the remainder of the study.  Mice were scored daily throughout the study.  Additionally, a 
notation of whether “spastic gait” was observed in an individual animal was recorded.  
“Spastic gait” was described as abnormally “stiff” or “flexed” extremities, compared to 
‘typical’ EAE, when mice develop a “limp” paralysis in which their legs drag.  
 
 
Analyses of Neurodegeneration by Fluoro-Jade C Staining of Degenerating Neural 
Elements 
 
 Mice were either euthanized by perfusion after two consecutive days of a 4.0 or 
higher score or at the end of the study.  Intracardiac perfusion was performed via the 
aorta.  Mice were perfused with 50 ml of ice cold PBS until fluid ran clear, followed by 
250 ml of ice cold 4% buffered paraformaldehyde.  Brain and spinal cords were extracted 
and post-fixed in 4% paraformaldehyde for 48 hours at 4C.  Brain tissues were sectioned 
at 30 um utilizing a sliding microtome.  Spinal cord tissue was paraffin embedded and 
sectioned at 10 um.  Sections were stained with hematoxylin and eosin and were used as 
reference. Fluoro-jade C (Millipore AG325) was utilized to label degenerating neural 
elements in both fixed, frozen brain tissue as well as paraffin embedded, fixed, spinal 
cord tissue.  Fluoro-jade C is a fluorescent derivative that stains degenerating neurons 
selectively 147. The Fluoro-jade C protocol was adapted from Kanthasamy, AG et. al 148.  
Brain and spinal cord sections labeled with Fluoro-jade C were analyzed while 
referencing the Interactive Atlas Viewer (atlas.brain-map.org) and Brown et al 148, which 
contained a comprehensive Fluoro-Jade C staining map of the entire CNS in MOG 
induced EAE35-55.  Quantification of Fluoro-jade C intensity was performed using image J 
software with a method adapted from Burgess et al 149.  A comprehensive analysis was 
performed throughout the brain and spinal cord to determine specific regions which had 
increased neurodegeneration.  Specific regions of the brain were imaged in order to 
determine if neurodegeneration was statistically different between groups based upon the 
mean fluorescence intensity from representative images of the specific region. The mean 
fluorescence intensity of 30 total images from 3 animals per group for Arbor Vitae and 
Corpus Callosum sections and 20 total images from 3 animals for VSCT sections were 
used in each statistical analysis. 
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CHAPTER 3.    ANTI-HNRNP A1 ANTIBODIES PENETRATE AND CAUSE 
DELETERIOUS EFFECTS IN NEURONS IN VITRO 
 
 
Introduction 
 
 Antibodies have been implicated in the pathogenesis of a number of autoimmune 
diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), 
paraneoplastic syndromes, multiple sclerosis (MS), and human T-lymphotropic virus type 
1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) (a viral 
model of MS). 93,94,97,98,150-154 The dominant theory asserts that upon cellular injury 
intracellular antigens are exposed to the adaptive immune response allowing for antibody 
response to the target antigen. It is generally believed that transected axons are vulnerable 
to an autoimmune response while healthy neurons are considered protected from a direct 
pathogenic effect.   The method by which antibodies cause disease is an ongoing area of 
research, however current data proposes that interactions between antibodies and various 
intracellular molecules cause inflammation, altered cellular messaging, and apoptosis.155  
The antibody response to hnRNPs seen in SLE patients provides some insight into this 
process of antibody-mediated disease.  SLE patients produce antibodies to hnRNP P2.156  
Following apoptosis of target cells, hnRNP P2 is transported to the cell surface and 
therefore is available to generate an autoimmune response.156  In neurological disease, 
previous data suggested that only neuronal surface antigens were reliable targets for 
pathogenic autoimmune responses. 157,158  This concept is now being challenged.  Current 
data suggest that antibodies have the ability to enter neurons in an epitope specific 
manner.  In autoimmune retinopathy, autoantibodies to enolase, a cytoplasmic glycolytic 
enzyme, were shown to penetrate neurons and alter the function of enolase.159  Another 
example is present in a model of stiff man syndrome in which anti-amphiphysin 
antibodies entered neurons and co-localized with presynaptic markers and altered 
gamma-aminobutyric acid (GABA) release in vivo.160  Such studies address important 
issues. However, to better understand the contribution of immune responses to intra-
neuronal antigens in the pathogenesis of immune-mediated neurological diseases, more 
information is required. 
 
 MS is a neurodegenerative disorder resulting in demyelination of neurons, which 
is increasingly associated with grey matter and neuronal degeneration. MS and 
HAM/TSP patients have been shown to produce autoantibodies to the intracellular RNA 
binding protein heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). 93,94,96-98,154  
IgG from MS and HAM/TSP patients reacted specifically with an epitope within the M9 
region of hnRNP A1, its nuclear localization/export sequence (NLS/NES). These 
antibodies decreased neuronal firing and contributed to the death of neuronal 
cultures.94,154 However, until now it remained unknown if anti-hnRNP A1 antibodies 
have the ability to penetrate neuronal cells.  Because autoantibodies to the M9 region of 
hnRNP A1 appear unique to MS and HAM/TSP patients and are not seen in healthy 
individuals, we decided to investigate whether antibodies that target the hnRNP A1-M9 
epitope can penetrate healthy neuronal cells and examine the possible deleterious effects 
that they might induce.   
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Direct Antibody Addition into Growth Media Results in Antibody Penetration into 
Neuronal Cells 
 
 In order to investigate the role of antibodies to hnRNP A1 on neuronal cells, we 
determined whether the antibodies had the ability to penetrate SK-N-SH neuronal cells.  
We utilized commercially available anti-hnRNP A1 antibodies that recognize the M9 
region of hnRNP A1 and control IgG antibodies to determine the antibodies’ ability to 
penetrate neuronal cells. To visualize antibody penetration, we labeled the antibodies 
with a red fluorescent dye – Atto-550-NHS dye as previously described.161  Atto-550-
NHS is a new label with high molecular absorption and quantum yield. Excitation and 
emission for Atto-550-NHS (Ex.556/Em.578nm) is similar to a well-known Cy3 dye. 
Atto-550-NHS labeled antibodies were added directly to the cell growth media at 
different concentrations (2, 4, 6, and 8 µg/mL) without any additional reagents. Cells 
were examined under Zeiss AxioObserver1 microscope in phase and fluorescence modes 
24 and 72 hours following treatment.  Cells treated with fluorescent label itself did not 
uptake the dye, suggesting that Atto-550-NHS was not responsible for antibody 
penetration (data not shown).  At the 24-hour point, the anti-hnRNP A1 and control IgG 
antibodies were found inside neuronal cells (Figure 3-1A).  Additionally, at 72 hours, 
penetration was seen in both groups.  Interestingly, quantification of the percentage of 
cells penetrated by antibodies reveals that the anti-hnRNP A1 antibodies penetrate the 
neuronal cells more readily than control IgG (Figure 3-1B).   These findings suggest that 
antibodies possess the ability to penetrate neuronal cells and that the anti-hnRNP A1 
antibodies penetrated more readily than control antibodies. 
 
 
Antibodies to hnRNP A1 Penetrate Neuronal Cells and Co-localize with Early 
Endosomes 
 
 Next, we sought to examine the mechanisms of cellular penetration. Since 
endocytosis is involved in the uptake of numerous molecules from the extracellular 
environment, we set out to determine whether endosomes were involved in antibody 
entry into neurons.  To accomplish this task, we performed localization studies and tested 
whether antibodies co-localized with early endosomes.  Early endosomes were pre-
labeled with GFP BacMam reagent (green) and antibodies with Atto-550-NHS (red).  As 
early as 6 hours after antibody addition, anti-hnRNP A1 antibodies co-localized with 
early endosomes (Figure 3-2A). Maximum co-localization was seen at 24 hours after 
antibody addition (Figures 3-2A and 3-2B).  At 48 hours, antibody co-localization with 
early endosomes was still present (Figure 3-2A), however the number of endosomes that 
contained antibodies was significantly less than at 24 hours.   The fact that co-localization 
is seen at multiple time points rather than just a single window of time, suggests that 
antibodies continually penetrate neuronal cells as long as there are still free antibodies in 
the extracellular media.  These results indicate that endocytosis appears to be the 
mechanism by which antibodies penetrate neuronal cells. 
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Figure 3-1. Localization of antibodies by immunocytochemistry in SK-N-SH cells.  
A. Following addition of antibodies to the media, Atto-550-NHS labeled anti-hnRNPA1 
antibodies specific to the M9 epitope and control antibodies (both in red) were found to 
penetrate neuronal cells. B. Quantification of antibody penetration percentage between 
the anti-hnRNP A1 treated and control rabbit IgG treated cells was performed using 
AxioVision Software. Five images were used per treatment from the 24 hour images. 
Antibody penetrated cells were divided by the total number of cells to give a percentage 
of antibody penetration. (Cells with antibodies per image/Total cells per image) x 100 = 
Penetration Percentage. Data was analyzed with one way ANOVA with standard error 
measurement (SEM). *P<0.05, **P<0.01. 
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Figure 3-2. Antibodies co-localize with early endosomes. 
Early endosomes labeled with BacMam particles GFP (green), antibodies with Atto550-
NHS (red). Examples of co-localization (yellow) are shown in boxes. Arrows in high-
powered images point to colocalized antibody example. Scale bar=10µm. 2B. 
Quantification of antibodies co-localized to early endosomes at 6, 24 and 48 hours after 
antibody addition to the media. Images were taken on fixed cells and number of co-
localized antibodies was calculated per cell at a given time point. Events were calculated 
in 10 cells per time point from two experiments (20 cells total per time point). Groups 
were analyzed with one-way ANOVA with Newman-Keuls multiple comparison test 
using SEM. *P<0.05, **P<0.01.   
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Antibodies to hnRNP A1 and IgG Penetrate Neuronal Cells via Clathrin Mediated 
Endocytosis and Not via Caveolar Mediated Endocytosis 
 
 Two main types of endocytosis occur in neuronal cells, clathrin and caveolar 
mediated endocytosis. 162,163  Molecules endocytosed into cells can traffic through one or 
both pathways.  We examined whether neuronal cells uptake antibodies via one or both 
of these pathways. To answer this question, we used competitive inhibitors of the 
individual pathways to determine whether antibody penetration was blocked.  To evaluate 
clathrin-mediated endocytosis we used Pitstop2 reagent, which selectively inhibits 
clathrin via inhibition of the clathrin terminal domain. 163,164.  With clathrin-mediated 
endocytosis inhibited, we witnessed complete blockage of the penetration of the 
antibodies, thus illuminating clathrin-mediated endocytosis is at least one mechanism by 
which antibodies penetrate neuronal cells (Figure 3-3A).  To assess whether caveolar-
mediated endocytosis was also involved in antibody entry into the cell we used nystatin, a 
lipid raft inhibiting agent, to block caveolar-mediated endocytosis 165.  When caveolar-
mediated endocytosis was blocked, we observed a standard amount of antibodies inside 
neuronal cells (Figure 3-3A).  Cells with nystatin did not differ from cells without any 
blocking reagent.  This suggests that caveolar-mediated endocytosis is not involved in the 
intracellular penetration of antibodies (Figure 3-3A).   To confirm our observation 
biochemically, we performed co-immunoprecipitation experiments. In these experiments, 
anti-hnRNP A1 antibodies or control rabbit IgG were bound to agarose-A beads.  The 
whole cell lysate was incubated with the beads overnight, complexes were eluted, 
immobilized onto PVDF membranes and probed with anti-clathrin antibodies. Beads 
without antibodies (B) served as negative control (Figure 3-3B). A clathrin band is seen 
in the whole cell lysate lane (L) confirming its presence in SK-N-SH cells. Signal is 
enriched in both the control IgG and anti-hnRNP A1-M9 lanes, but not in the blank lane 
(B), indicative of antibody binding to clathrin, and thus confirming the specificity of 
observation seen by immunocytochemistry. Taken together, these results demonstrate 
that antibodies penetrate neuronal cells via clathrin-mediated endocytosis. 
 
 
Anti-hnRNP A1 Antibodies Deplete Cellular ATP 
 
 Based upon our previous data showing antibody entry into neurons, we 
hypothesized that there would be altered cellular events related to the presence of 
antibodies inside the cells.  Previously, we showed that transfection of anti-hnRNP A1-
M9 antibodies into dNT-2 neurons resulted in expression of neurodegenerative markers 
and cell death within 7 days.154 Transfection of normal rabbit IgG did not have the same 
effect. Thus, it appears that anti-hnRNP A1-M9 antibodies play a role in neuronal 
degeneration. In this study, we carried out all experiments without transfection and 
examined the possible effects of these antibodies on SK-N-SH neuronal cells. Since ATP 
is essential to cell health and function, we determined if cellular ATP levels, a measure of 
cellular viability, were altered by anti-hnRNP A1 antibodies.   We performed the 
CellTiter-Glo Luminescent Cell Viability Assay to determine the ATP levels of the 
neuronal cells in untouched as well as in the precence of the antibodies.  In these 
experiments we used unlabeled anti-hnRNP A1 or IgG. Our results reveal that ATP levels   
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Figure 3-3. Antibodies (labeled red) penetrate SK-N-SH cells via clathrin-
mediated endocytosis. 
A. Addition of Pitstop2 reagent prevented clathrin-mediated endocytosis of both anti-
hnRNP A1 and IgG into SK-N-SH cells. Addition of nystatin, used to block caveolar 
mediated endocytosis, did not block penetration. B. Clathrin immunoprecipitation on 
agarose A-linked anti-hnRNPA1 and control IgG. L= SK-N-SH cell lysate. B = Agarose 
A beads, IgG = control IgG attached to agarose A beads, A1= anti-hnRNPA1 antibodies 
attached to agarose A beads. Both control IgG and anti-hnRNP A1 antibodies bound 
clathrin, confirming the observation by immunocytochemistry.  
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were compromised by as early as 48 hours after anti-hnRNP A1 antibody addition 
(Figure 3-4). Addition of normal rabbit IgG did not significantly affect ATP levels in 
these cells.  The alteration of cellular ATP levels induced by anti-hnRNP A1 antibodies 
could lead to a multitude of deleterious downstream effects on the neuronal cells.  
 
 
Anti-hnRNP A1 Antibodies Are Not Cytotoxic 
 
 Considering that anti-hnRNP A1-M9 antibodies diminished the viability of 
neuronal cells, we performed the Cytotox-ONE Cytotoxicity Assay to determine the 
possible cytotoxic effects of anti-hnRNP A1-M9 antibodies on neuronal cells.  
Cytotoxicity in these experiments was determined by the amount of membrane damage to 
the cells as measured by the Cytotox-ONE Cytotoxicity Assay.  SK-N-SH cells were 
seeded in 96-well plate in triplicate for each group: 1) untouched, 2) cells with control 
rabbit IgG, 3) cells with anti-hnRNP A1 antibodies. All groups were normalized based on 
relative fluorescence of untouched cells. Plates were evaluated at 24, 48, and 72 hours 
after antibody addition. There were no statistical differences in cytotoxicity between the 
anti-hnRNP A1 and control antibodies, suggesting that neither control rabbit IgG or anti-
hnRNP A1-M9 antibodies were cytotoxic to SK-N-SH cells. (Figure 3-4B). 
 
 
Anti-hnRNP A1 Antibody Increased Apoptosis in Neuronal Cells 
 
 Considering the effects of anti-hnRNP A1 on neuronal viability (ATP levels), we 
hypothesized that the anti-hnRNP A1 treated cells would show an increase in apoptosis 
compared to control antibodies.  Caspases 3 and 7 are the executioner apoptosis caspases.  
In order to examine the levels of these caspases we used the ApoOne Homogenous 
Caspase 3/7 Kit (Promega).  Cells treated with anti-hnRNP A1 antibodies were compared 
to control IgG and untouched cells at 24, 48 and 72 hours after antibody addition.  No 
differences were detected between the groups at 24h. However at 48h, cells treated with 
anti-hnRNP A1-M9 antibodies showed increased Caspase 3/7 levels in comparison to 
control IgG.  This trend continued at the 72-hour time point showing a significant 
increase in Caspase 3/7 activity in the anti-hnRNP A1-M9 antibody treated group 
compared to controls (Figure 3-4C).  These results reveal that one mechanism by which 
anti-hnRNP A1-M9 antibodies alter cell viability in neuronal cells is due to an increase in 
Caspase 3/7 activity leading to apoptosis of neuronal cells. 
 
 
Anti-hnRNP A1 Antibodies Cause Redistribution of Endogenous hnRNP A1 Protein 
 
 Based upon the specificity of an antibody-antigen interaction, we hypothesized 
that the anti-hnRNP A1 antibodies not only penetrated neurons and localized to early 
endosomes, but also targeted endogenous hnRNP A1 protein.  In order to resolve this 
question, we performed double labeling experiments in which we added rabbit Atto550 
labeled anti-hnRNP A1 and control antibodies to neuronal cells, fixed and permeabilized 
the cells and then labeled endogenous hnRNP A1 with mouse monoclonal anti-hnRNP   
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Figure 3-4. Anti-hnRNP A1 antibodies caused an increase in apoptosis and 
depletion of ATP levels.  
A. Cellular ATP levels are significantly reduced when SK-N-SH cells were exposed to 
anti-hnRNP A1 antibodies. B. Antibodies were not cytotoxic to the SK-N-SH cells 
(Percent cytotoxicity was normalized based on the numbers detected in untouched cells). 
C. In contrast to control antibodies, reduced levels of caspase 3/7 were seen at 48 and 72 
hours after anti-hnNRP A1 antibodies were added to the media. Results were analyzed 
with two-way AN 
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C. 
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A1 followed by secondary anti-mouse FITC antibodies (Figure 3-5).   In contrast to 
control antibodies, our results reveal that following anti-hnRNP A1-M9 antibody addition 
there is a redistribution of endogenous hnRNP A1 from being primarily nuclear to being 
equally distributed in the nucleus and in cytoplasm (Figures 3-5A and 3-5B). Total 
densitometric means of FITC expression were quantified for both the nuclear and 
cytoplasmic portions of the cells in all experimental groups using Axiovision software. 
The densitometric mean of FITC expression of the nuclear and cytoplasmic cellular 
portions was used to quantify a nuclear to cytoplasmic ratio for each experimental group 
(Figure 3-5B).  These analyses indicate that the anti-hnRNP A1 treated cells have a 
significantly altered nuclear to cytoplasmic expression ratio of endogenous hnRNP A1 
when compared to untouched control and the IgG treated cells.  Based upon the data 
presented, it suggests that anti-hnRNP A1 antibodies penetrate neuronal cells and have a 
specific effect upon endogenous hnRNP A1 protein resulting in the protein getting 
trapped in the cytoplasm.  Alteration of the endogenous protein could have downstream 
effects upon mRNA binding partners transported by hnRNP A1 under normal conditions. 
 
 
Conclusions 
 
 The role of autoantibodies and their ability to target intracellular antigens is an 
important focal area of research for autoimmune disorders.  The notion that cellular 
injury is initiated and swiftly followed by intracellular antigens being exposed to the 
adaptive immune response resulting in the ability of antibody response to the target 
antigen prevails as the dominant theory.  Autoantibodies produced by patients with 
autoimmune disorders have been implicated in the pathogenesis of various diseases such 
as SLE, RA, paraneoplastic syndromes, MS and HAM/TSP. 12,93,94,97,98  In previous work 
it has been shown that patients with MS and HAM/TSP produce autoantibodies to the 
nuclear shuttling protein hnRNP A1, and specifically to its M9 region.12  The 
autoantibodies specific to hnRNP A1 have been implicated in the pathogenesis of MS 
and HAM/TSP, however until now it was not clear how these antibodies might cause 
target cell damage.   
 
 Anti-recoverin antibodies that are present in patients with cancer associated 
retinopathy (CAR) syndrome were previously shown to penetrate E1A.NR3 cells via 
endocytosis.144  In this study, we have shown that antibodies to hnRNP A1 are capable of 
penetrating SK-N-SH neuronal cells through clathrin-mediated endocytosis.  Compared 
to control antibodies, the anti-hnRNP A1 antibodies penetrated neuronal cells more 
readily and showed a higher level of co-localization within early endosomes. 
Interestingly, anti-hnRNP A1 antibodies added directly into the media penetrated at 
nearly the same efficiency seen previously through transfection methods of anti-hnRNP 
A1 antibodies into the SK-N-SH neuronal cells.12  The fact that the method of antibody 
penetration occurs through endosomes gives great insight because endocytosis is a 
general method of cellular uptake of various molecules and it occurs in various neuronal 
cell types. Therefore, it would be important to note that this method of antibody 
penetration might be taking place in a multitude of neurons throughout the nervous 
system.  Retrograde axonal transport through signaling endosomes has been shown as a   
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Figure 3-5. Anti-hnRNP A1 antibodies cause redistribution of endogenous 
hnRNP A1 in SK-N-SH cells.  
A. Atto-550-NHS labeled anti-hnRNPA1 or control antibodies (red) were added to the 
cells. 24 hours later cells were fixed, washed and permeabilized. Endogenous hnRNP A1 
was labeled with primary mouse monoclonal antibodies followed by FITC anti-mouse 
secondary antibodies. White borders outline nuclei, yellow - cytoplasm. B. Quantification 
of endogenous hnRNP A1 redistribution in comparison to untouched cells and cells with 
control IgG.  Nuclear to cytoplasmic fluorescence ratio calculated using densitometric 
means, n=20 cells from three separate experiments. One way ANOVA was utilized using 
SEM. *P<0.05, **P<0.01.     
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growing area of research in neurodegenerative disorders.  A link has been formulated 
between disruption of retrograde transport and a variety of neurodegenerative diseases 
138.  Various neurotrophic factors such as nerve growth factor (NGF), brain derived 
neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4) have 
been shown to bind specific Trk receptors at axon terminals and are ultimately 
transported retrogradely via signaling endosomes by microtubule dependent dynein 
motors. 138,166,167  Dynein function disruption has been shown to lead to 
neurodegeneration in both mice and human disease.138  Furthermore, it has also been 
presented that both retrograde and anterograde transport malfunction can result in a 
“traffic jam” of sorts, displaying that mutations in kinesins as well as dynein can 
influence signaling endosomes in a negative manner 138,168.  Of specific interest, 
hereditary spastic paraplegia (HSP) a disease that is clinically indistinguishable from 
progressive MS and HAM/TSP, exhibits the “dying back phenomena” specific to 
disruption of retrograde transport as the disease is seen to progress in a distal to proximal 
progression 138.  Several forms of HSP contain causative mutations of molecular motors 
or in other proteins that affect axonal transport indirectly. 138,169-171  These studies provide 
insight into future studies to assess whether autoantibodies to hnRNP A1 produced by 
MS and HAM/TSP patients have an effect upon retrograde transport, thus providing a 
possible mechanism for the distal to proximal neurodegeneration seen in patients with 
MS.   
 
 In these studies, we show for the first time that antibodies to hnRNP A1 have the 
ability to penetrate healthy neuronal cells and cause negative effects on the intracellular 
environment.  Compared to control antibodies, anti-hnRNP A1 antibodies significantly 
depleted cellular ATP levels and caused significant increases in caspases 3/7 levels 
leading to apoptosis in SK-N-SH neuronal cells.  It is important to note that decrease in 
cellular ATP often correlates with the initiation of apoptosis leading to cell death.172  In 
addition, we showed that anti-hnRNP A1 antibodies caused a redistribution of 
endogenous hnRNP A1 from being primarily nuclear to being equally nuclear and 
cytoplasmic.  The epitope recognized by the anti-hnRNP A1 antibodies is AA 293-304, 
located at the C-terminal of the M9 sequence, which is hnRNP A1’s NLS/NES.97  The 
anti-hnRNP A1 antibodies targeted this sequence and altered its nuclear-cytoplasmic 
transport. Importantly, Michael et al 126 showed that deletion mutations in this region of 
M9 result in loss of nuclear import and export of hnRNP A1. Taken together, these data 
indicate that the anti-hnRNP A1 antibodies specifically targeted M9 and in doing so, 
caused a change in localization of hnRNP A1, which considering its critical role in 
cellular function, would likely have deleterious effects on neurons. Consequently, we 
hypothesize that anti-hnRNP A1 autoantibodies found in patients with MS and 
HAM/TSP might contribute to the pathogenicity of the disease, rather than merely 
disease markers.   
 
 In summary, these experiments showed that anti-hnRNP A1 antibodies penetrate 
SK-N-SH neuronal cells through clathrin-mediated endocytosis and enter early 
endosomes.  In addition, the antibodies significantly altered ATP levels and increased 
Caspase 3/7 levels that ultimately lead to apoptosis and cell death.  Further, our studies 
reveal that anti-hnRNP A1 antibodies also have specific effects on hnRNP A1.  These 
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findings have implications concerning the pathogenesis of MS and HAM/TSP, in which 
neuronal damage and neurodegeneration are important features.  The findings presented 
in AIM 1 set the foundation for the next two aims. By determining the mechanism of 
antibody entry as well as various negative effects compromising the viability of the 
antibody-treated cells, the groundwork was set to delve further into a specific mechanism 
causing the cell death.  In AIM 2 we seek to answer these questions by assessing 
antibodies possible role in stress granules, determining mRNA binding partners of 
hnRNP A1 protein, and investigating translational repression of selected genes of interest 
due to antibodies effect on neuronal cells. 
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CHAPTER 4.    ANTI-HNRNP A1 ANTIBODIES CO-LOCALIZE WITH RNA 
GRANULES AND ALTER SPASTIC PARAPLEGIA GENES IN NEURONS 
 
 
Aim 2 Introduction 
 
 Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system 
(CNS) of unknown etiology.  It is believed to occur in individuals with genetic 
susceptibility.173-176  Disease in these individuals might be initiated by an environmental 
stimulus, which results in an inflammatory response directed towards CNS targets.  The 
resulting autoimmune response leads to demyelination and axonal degeneration within 
the CNS.  
 
 MS patients have been shown to produce autoantibodies to various myelin and 
non-myelin antigens.  For example, patients develop autoantibodies to myelin 
oligodendrocyte glycoprotein (MOG), myelin associated glycoprotein (MAG), myelin 
basic protein (MBP), and proteolipid protein (PLP).100-103  These myelin autoantibodies 
have been found in the cerebrospinal fluid (CSF) and serum of MS patients. 
Contradictory studies exist as to whether these myelin-associated antibodies are 
pathogenic. 11,102,104-109,177  In addition to myelin antigens, MS patients have been shown 
to produce autoantibodies to various neuronal antigens such as neurofascin (NF-186), 
neurofilament light chain (NF-L), and to glial antigens such as KIR4.1 and glial fibrillary 
acidic protein (GFAP). 112-114,178 Importantly, studies have shown these target specific 
antibodies to be associated with increased disease progression in animal models (NF-186) 
and cerebrospinal fluid (CSF) from human samples (NF-L, GFAP) respectively.112-114   
 
Autoantibodies produced by MS patients are specific to the M9 region of hnRNP 
A1.1,2,11,12,95,99   Anti-hnRNP A1 antibodies enter neuronal cells through a mechanism 
involving clathrin-mediated endocytosis.1  Once inside neuronal cells, anti-hnRNP A1 
antibodies reduce cellular ATP levels, increase apoptosis, and cause endogenous hnRNP 
A1 mislocalization from a primarily nuclear localization to a near 1:1 nuclear to 
cytoplasmic ratio.1  Furthermore, anti-hnRNP A1 antibodies transfected into human 
neuronal cells in vitro altered RNA levels of the spastic paraplegia genes (SPGs) spastin 
(SPG4), spartin (SPG20), and paraplegin (SPG7) as shown by microarray.12  The 
alterations in the SPGs were further confirmed in neurons purified from human brain 
samples of MS patients compared to normal controls by Real-Time PCR.12  Mutations 
within the SPGs are associated with the neurologic disease hereditary spastic paraplegia, 
which is clinically similar to some forms of MS.133 
 
Three main types of granules exist within neuronal cells: stress granules (SGs), 
processing bodies (P bodies), and neuronal transport RNPs (also known as neuronal 
‘transport granules’).179  SGs develop as the result of various cellular stressors.179  SGs 
harbor translationally repressed RBPs and their mRNA cargo during cellular stress.  Once 
the cell has returned to homeostasis; the SGs sort, remodel, and export the various 
mRNAs for reinitiation or storage.179  P bodies act as sites of translational repression and 
degradation for the cell.179  P bodies do not contain ribosomal subunits and are the waste 
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management system of the cell.  Neuronal transport granules act as motile granules to 
transport RBPs and their translationally arrested mRNA cargoes to sites of translation.179   
In summary, SGs harbor translationally arrested RBPs and their cargo during times of 
cellular stress until homeostasis is achieved, P bodies manage the waste of the cell, and 
neuronal transport granules are responsible for transport of RBPs and their translationally 
arrested cargoes, which upon arrival to designated sites in the neuron, undergo 
translation.  
 
In this section we sought to determine anti-hnRNP A1 antibodies interaction with 
the three types of neuronal granules (SGs, P bodies, and neuronal ‘transport granules’).  
Additionally, we tested whether the SPGs (SPG4 and SPG7) are mRNA binding partners 
of hnRNP A1 protein. Moreover, we resolved whether anti-hnRNP A1 antibodies effect 
RNA expression of the mRNA binding partners. Finally, we determined downstream 
effects of anti-hnRNP A1 antibodies on translation of these clinically relevant mRNA. 
 
 
Aim 2 Results 
 
 
Anti-hnRNP A1 Antibodies Colocalize with SGs but Not P Bodies or Neuronal 
Transport Granules 
 
 Neuronal granules play a crucial role in the trafficking of various RBPs and their 
mRNA cargoes in neuronal cells.  P bodies and neuronal transport granules are present 
when cells are in homeostasis, whereas SGs only occur during cellular stress.179  SGs 
harbor RBPs and their cargo in a state of translational repression during a stress response 
until the cell has returned to a homeostatic state. Since patients with MS produce 
antibodies to hnRNP A1, which is an RBP, we hypothesized that the anti-hnRNP A1 
antibodies would colocalize to RBP specific granules within neurons.  Previously, we 
have shown that anti-hnRNP A1 antibodies entered neurons by clathrin-mediated 
endocytosis to a higher degree than control IgG (p≤0.01).1  Therefore, we further 
hypothesized that anti-hnRNP A1 antibodies would cause cellular stress resulting in SG 
formation at higher levels than control IgG.  To answer this question, anti-hnRNP A1 
(ab4791) specific antibodies as well as isotype-matched control IgG labeled with 
Alexafluor 488 were added to the media of SK-N-SH neuronal cells in culture.  After a 
48 hour incubation, cells were fixed and labeled for SGs (TDP-43), P bodies (GW182), 
and neuronal transport granules (hnRNP A2B1) utilizing neuronal granule components 
previously identified by Kiebler et al.179  Antibody treated groups were compared to 
untreated control SK-N-SH cells.  Our results revealed that both anti-hnRNP A1 
antibodies and control IgG resulted in SG formation and both colocalized with SGs 
(Figure 4-1A).  However, anti-hnRNP A1 antibodies penetrated neuronal granules and 
colocalized with SGs more readily and the differences were statistically significant 
(p≤0.05), suggesting that hnRNP A1 antibodies specifically bound hnRNP A1 within 
SGs (Figure 4-1B, Table 4-1).  Neither of the antibodies colocalized with P bodies or 
neuronal transport granules (not shown). 
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Figure 4-1. Antibodies co-localize with stress granules in SK-N-SH neurons.  
A. SK-N-SH cells were seeded into 8 chamber slides. Cells were treated with either anti-
hnRNP A1-M9 antibodies, IgG, or left untouched.  Following a 48 hr incubation, cells 
were fixed with 4% Paraformaldehyde, blocked and permeabilized, and stained for stress 
granules with anti-TDP-43 antibodies. The figure shows that both anti-hnRNP A1-M9 
antibodies and control IgG cause stress granule formation and colocalize to stress 
granules. B. Anti-hnRNP A1-M9 antibodies colocalize at a two-fold higher percentage 
than IgG. The increase in colocalization was quantified using a one-tailed t-test based on 
a previously observed trend. *P<0.05, **P<0.01.   
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Table 4-1. Quantification of antibody colocalization with stress granules. 
 
Culture condition IgG A1 
Cells counted 537 530 
 
Colocalizations 19 30 
 
Colocalization to cell 
percentage 
3.54% 
 
5.66% 
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SPG4 and SPG7 RNA Bind hnRNP A1 Protein 
 
 After determining that both anti-hnRNP A1 antibodies and control IgG colocalize 
within SGs, we sought to determine whether anti-hnRNP A1 antibodies have a specific 
effect on the RNA metabolism of hnRNP A1 protein’s RNA cargo.  In order to 
accomplish this goal we needed to determine the RNA binding partners of hnRNP A1 
protein.  Previous studies have shown that anti-hnRNP A1 antibodies transfected into 
neuronal cells resulted in altered levels of specific genes when determined by 
microarray.12  Furthermore, these studies also confirmed the alteration of a subset of 
these genes in neurons isolated from MS patient brain compared to control brain.12  
Among the genes that were altered in both neuronal cell lines and neurons isolated from 
MS brains were the SPGs (SPG4, SPG7, and SPG20).12  Various mutations in the SPGs 
result in multiple forms of the human disease hereditary spastic paraparesis (HSP), which 
is clinically similar to progressive forms of MS.133  Taken together, we determined it was 
necessary to resolve whether these clinically relevant genes bound hnRNP A1.  
 
 To evaluate which RNAs might theoretically bind hnRNP A1, we used the RNA 
Binding Protein Data Base (RBPDB, http://rbpdb.ccbr.utoronto.ca/). This database 
contains the unique RNA binding sequences that are required for RNA to bind RNA 
binding domains of an RBP. The user enters an RNA sequence into the RBPDB. The 
RBPDB scans the RNA sequence and reports out all RBPs that might bind to it, and the 
exact sequence and its location within the RNA sequence input. Using the RBPDB, we 
found that spastin (SPG4) contains a 100% binding sequence (NM_014946, b.3283-
3288) match with hnRNP A1’s RNA binding sequence in its non-coding sequence. 
Coding regions tend not to bind RBPs, so that the coding sequence remains 
unencumbered for translation. SPG7 and SPG20 had variable degrees of RNA binding 
sequence alignment. Besides the RNA sequence, a number of variables contribute to 
RNA binding, such as the ability for RNAs to bind multiple RBPs, the quantity of the 
RBP present in the cells being analyzed and the strength of the binding between the RNA 
and the RBP.180 Thus, RNA binding to hnRNP A1 is not the only mechanism by which 
RNAs might be altered in this system. Each RNA has to be examined experimentally, 
which we did in the following experiments. hnRNP A1 RNA was used as a positive 
control because it previously was shown to be an RNA binding partner of hnRNP A1 as 
determined by CLIP analysis.181 
 
To test whether the target RNAs bound hnRNP A1, we performed RNA 
immunoprecipitation.  Protein A/G agarose beads were labeled with anti-hnRNP A1 
antibodies to elute hnRNP A1 protein as well as bound RNA.  In parallel, protein A/G 
agarose beads were labeled with isotype-matched IgG (control).  SK-N-SH lysates were 
incubated with the antibody-bound beads.  Bound protein-RNA complexes were eluted 
with elution buffer.  The eluents were then run on Western blot (Figure 4-2).  Each lane 
was probed for hnRNP A1 protein to prove specificity of the elution of hnRNP A1 from 
the immunoprecipitation compared to the IgG control (Figure 4-2A).  After determining 
the specificity of the immunoprecipitation, RNA was extracted from the eluents using the 
RNA-Stat 60 protocol.182  Following first strand synthesis, the cDNA was used for 
quantitative RT-PCR to determine if the target RNAs chosen from the microarray data  
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Figure 4-2. RNA immunoprecipitation.  
SK-N-SH cells lysates were incubated with protein A/G agarose beads labeled with 
antibodies to either hnRNP A1 (ab4791) or IgG (Millipore 12-370).  Proteins and any 
bound RNA partners were eluted from the beads. A. Protein eluents were run on 10% 
Tris-glycine gels for Western blotting.  Gels were transferred to nitrocellulose 
membranes and were probed for hnRNP A1 protein (Millipore 4B10 05-1521). L= 
Untouched SK-N-SH lysate, A1= hnRNP A1 bound agarose beads eluent, IgG= IgG 
bound agarose beads eluent. The blots show that hnRNP A1 was present in the lysate (L) 
and the anti-hnRNP A1 IP (A1) but not in the control IgG IP (IgG).  B.  RNA was 
isolated from protein eluent for each group using the RNA-stat 60 protocol. cDNA was 
utilized for RT-PCR probing for genes of interest.  Values within groups were normalized 
to GAPDH.  hnRNP A1 RNA was utilized as a positive control. Results revealed that 
hnRNP A1, SPG4, and SPG7(n.s.) are RNA binding partners of hnRNP A1.  Data was 
analyzed using student t-test utilizing SEM. *P<0.05, **P<0.01.   
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were present, indicative of their binding to hnRNP A1 protein.  GAPDH was used as a 
quality control to normalize each group. Our results revealed that RNA of hnRNP A1, 
SPG4 and to a lesser extent, SPG7 bound hnRNP A1 (Figure 4-2B).  In contrast, SPG20 
did not bind to hnRNP A1 (Figure 4-2B). 
 
 
Anti-hnRNP A1-M9 Antibodies Alter SPG4 and SPG7 Protein Levels by Western 
Blot 
 
In previous studies, we showed that exposure of anti-hnRNP A1 antibodies to SK-
N-SH neuronal cells in culture caused mislocalization of endogenous hnRNP A1, from a 
predominantly nuclear, to an equal nuclear to cytoplasmic distribution.1  In the present 
study, we showed that anti-hnRNP A1 antibodies localized to SGs within the neuronal 
cytoplasm. This suggests that the anti-hnRNP A1 antibodies targeted hnRNP A1 protein 
in the cytoplasm, which resulted in SG formation. Because mislocalization of RNA 
binding proteins from the nucleus is associated with changes in RNA metabolism 
(including translation), we set out to determine whether anti-hnRNP A1 antibodies 
caused changes in the RNA expression of RNAs bound to hnRNP A1 protein.183  
Specifically, we hypothesized that protein levels of hnRNP A1’s RNA binding partners 
(hnRNP A1, SPG4 and SPG7) would be altered whereas RNAs that did not bind hnRNP 
A1 (SPG-20) would not. Additionally, since anti-hnRNP A1 antibodies and normal IgG 
both initiated SG formation and both colocalized within SGs, we wanted to determine if 
anti-hnRNP A1 antibodies caused specific downstream effects (i.e. altered translation) 
upon the bound RNAs compared to isotype control IgG. We performed these studies by 
adding 8ug/ml of anti-hnRNP A1-M9 antibodies or isotype-matched control IgG, to SK-
N-SH neuronal cells. These data were compared to untreated SK-N-SH neuronal cells run 
in parallel. Cells were incubated with antibodies for 48 hours in complete growth media. 
Following the incubation period, cells were lysed and proteins extracted for Western 
blotting. Beta-actin was used as a control for protein expression. There was no difference 
in beta-actin expression between the three groups (Figure 4-3). Western blots showed 
that the anti-hnRNP A1 antibodies had a small effect upon hnRNP A1 protein levels and 
a profound reduction of SPG4 and SPG7 protein levels (Figure 4-3). There was no 
change in SPG20 protein levels, whose RNA did not bind hnRNP A1 (Figure 4-3). 
Taken together, these data indicate that in contrast to control IgG (which also localized to 
SGs), anti-hnRNP A1 antibodies specifically altered the translation of RNAs that bind 
hnRNP A1.  It is likely that these downstream protein effects are largely due to the 
specificity of anti-hnRNP A1 antibodies for M9, hnRNP A1’s nucleocytoplasmic 
transport domain. 
 
 
Aim 2 Conclusions 
 
Autoantibodies to various myelin as well as neuronal antigens have been 
implicated in the pathogenesis of MS.12,100-107,109,112-114,177  Antibodies produced against 
myelin antigens such as MOG, MBP, MAG, and PLP have been associated with 
demyelination in patients with MS, however some of these studies have been  
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Figure 4-3. Anti-hnRNP A1 antibodies alter protein levels as measured by 
Western blot. 
SK-N-SH cells were cultured and treated with anti-hnRNP A1 antibodies or control IgG. 
Following a 48 hour incubation, cells were lysed and protein lysate was run on 10% Tris-
glycine gels for Western blot analysis.  Gels were transferred to nitrocellulose 
membranes, blocked, and probed for Beta Actin (control), hnRNP A1, SPG4, SPG7, and 
SPG20.  Results revealed hnRNP A1, SPG4, and SPG7 had depleted protein values in 
anti-hnRNP A1-M9 antibody treated cells compared to controls. (L – lysate). 
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contradictory.12,100-107,109,177  Furthermore, experiments involving antibodies to neuronal 
antigens such as NF-L and NF-186 suggest their role in neurodegeneration and possible 
disease markers of clinical progression.12,112-114   
 
  Previous studies have shown that patients with MS produce antibodies to hnRNP 
A1 while healthy controls as well as patients with other neurologic disease have no titer 
specific to hnRNP A1.1,2,12,95,97,99  hnRNP A1 is an RBP highly expressed in neurons 
responsible for trafficking of various mature mRNA from the nucleus to the cytoplasm 
for translation.  hnRNP A1 has a C-terminal region termed ‘M9’, which is its NES/NLS 
responsible for the nuclear - cytosolic trafficking of hnRNP A1.1,2,11,12,94,95,97,99  The 
antibodies produced by MS patients are specific to this M9 region.1,2,11,12,95,99  Our 
previous studies have shown that endogenous hnRNP A1 was redistributed from a 
primarily nuclear localization to an equal nuclear/cytoplasmic mislocalization due to the 
specificity of the anti-hnRNP A1-M9 antibodies.1  Additionally, our data shows that the 
specificity of the anti-hnRNP A1 antibodies resulted in markers of neurodegeneration 
including decreased cellular ATP levels and increased apoptosis of neurons 1. The current 
studies show that anti-hnRNP A1 antibodies cause some cellular stress resulting in 
formation of SGs to which the antibodies colocalize. Additionally, we demonstrate that 
SPG4 and SPG7 are RNA binding partners of hnRNP A1.  Furthermore, we determined 
that anti-hnRNP A1 specific antibodies have profound effects upon specific RNA binding 
partners of hnRNP A1 protein.  Specifically, we showed that SPG4 and SPG7 protein 
expression are markedly reduced due to the specificity of anti-hnRNP A1 antibodies 
compared to isotype control IgG.  
 
 Taken together, these studies suggest a mechanism by which autoantibodies cause 
neurodegeneration. One of hnRNP A1’s many roles in RNA metabolism (‘ribostasis’) is 
to bind RNA, transport RNA from the nucleus to the cytoplasm, where it undergoes 
translation.184 hnRNP A1 is then quickly transported back to the nucleus. Thus, under 
normal cellular homeostasis, hnRNP A1 is predominantly localized to the nucleus. Our 
data indicate that the sequence of events by which anti-hnRNP A1 antibodies cause 
neurodegeneration is as follows. First, anti-hnRNP A1 antibodies enter neurons by 
clathrin-mediated endocytosis. Second, the anti-hnRNP A1 antibodies bind M9, which is 
hnRNP A1’s nucleocytoplasmic shuttling domain. The binding interrupts the normal 
transport of hnRNP A1 into the nucleus, thus hnRNP A1 is mislocalized to the 
cytoplasm, which results in cellular stress and SG formation. The anti-hnRNP A1 
antibodies localize to SGs, where they cause translational repression of SPG4 and SPG7, 
two clinically relevant RNAs, which now have been shown to bind hnRNP A1. Thus, 
anti-hnRNP A1 antibodies bind M9, which causes mislocalization of hnRNP A1 to the 
neuronal cytoplasm, SG formation, translational repression of RNA bound to hnRNP A1 
and subsequent neurodegeneration.1,2,11,12,95,99 
 
It is important to note that mutations in the genes affected (SPG4, SPG7) result in 
various forms of HSP.133  HSP is a genetically inherited spastic disorder similar clinically 
to MS.133  Mutations in SPG4 account for the most common autosomal dominant form of 
HSP.133  Additionally, SPG7 is a gene associated with mitochondrial function, 
specifically with mitochondrial respiratory chain complexes I and IV.185  It was shown 
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that patients with HSP resulting from mutations in SPG7 showed a significant decrease in 
mitochondrial respiratory chain complexes I and IV.185  Previously we have shown 
depleted ATP levels in vitro due to the addition of anti-hnRNP A1 antibodies.  In this 
article we show that anti-hnRNP A1 antibodies alter protein levels of SPG7 in vitro.  In 
concurrence with the studies in HSP patients with depleted mitochondrial respiratory 
chain complexes, our data suggests that altered SPG7 levels due to anti-hnRNP A1 
antibodies might act in a similar mechanism to the SPG7 mutations seen in patients with 
autosomal recessive HSP.  
 
In summary, we have shown that anti-hnRNP A1 antibodies cause cellular stress 
resulting in SGs to which the antibodies colocalize.  Additionally, we determined that 
SPG4, and SPG7 are RNA binding partners of  hnRNP A1, which are translationally 
repressed due to the specificity of anti-hnRNP A1 antibodies. These studies emphasize 
the importance of autoantibodies to non-myelin antigens in the pathogenesis of MS and 
shed insight into a possible mechanism of how autoantibodies to hnRNP A1 cause 
changes in neuronal function which ultimately leads to neurodegeneration.  The work 
presented in AIM 2 builds upon the work previously displayed in AIM 1.  We have 
shown further trafficking information concerning antibodies following penetration of 
neuronal cells.  We have shown that antibodies not only cause stress resulting in stress 
granules, but also that the antibodies colocalize to stress granules.  Furthermore, we have 
further exhibited that the anti-hnRNP A1 antibodies have a specific effect that is not 
present in the IgG treated cells.  Anti-hnRNP A1 antibodies specificity leads to 
translational repression of the SPGs (SPG4 and SPG7) which could expose a possible 
mechanism of cell death.  The data combined from the first two AIMs provides ample 
ground work set for the final AIM to make the transition into a murine model in order to 
determine if antibody specific neurodegeneration translates from an in vitro model to an 
in vivo model of MS.   
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CHAPTER 5.    ANTI-HNRNP A1 ANTIBODIES INCREASE 
NEURODEGENERATION IN EXPERIMENTAL AUTOIMMUNE 
ENCEPHALOMYELITIS (EAE), AN ANIMAL MODEL OF MS 
 
 
Introduction 
 
 In vitro studies have shown that anti-hnRNP A1 antibodies whose epitope 
overlapped the immunodominant epitope recognized by MS patients caused 
neurodegeneration in neuronal cell lines. In this study, we show that injection of anti-
hnRNP A1 antibodies in mice with experimental allergic encephalomyelitis (EAE) 
worsen clinical disease, alter the clinical phenotype of the mice and cause 
neurodegeneration in specific central nervous system (CNS) pathways. One pathway 
affected was the ventral spinocerebellar tract (VSCT), which showed preferential 
neurodegeneration compared to control groups consistent with ‘dying back’ axonal 
degeneration. Taken together, these data suggest that antibodies contribute to 
neurodegeneration in immune-mediated disease of the CNS. 
 
Neurodegeneration, including neuronal and axonal damage, has been shown to 
contribute to the pathogenesis of multiple sclerosis (MS).7,9,13,186-188 Manifestations of 
neurodegeneration have been observed using neuroradiological, neuropathological and 
animal studies of MS. For example, magnetic resonance imaging (MRI) brain images of 
MS patients show axonal damage as well as brain and spinal cord atrophy, which 
correlate with neurological disability.189,190 Pathologically, accumulation of amyloid 
precursor protein (APP) 15,191 and staining for non-phosphorylated neurofilament (SMI-
32) 9 (both markers of axonal injury) showed that axonal damage is a major component 
of MS lesions.9,187,192,193 Importantly, several studies have shown the presence of 
neurodegeneration throughout the disease course of MS, not just during latter progressive 
phases of disease, as was originally thought.187  In experimental allergic 
encephalomyelitis (EAE), an animal model of MS, data indicate that (like in MS) 
neuronal and axonal damage are present throughout the course of the disease, and thus 
contribute to the neurologic disability displayed by the animals.148,194,195 
 
 Antibodies that target neuronal and axonal antigens are one of several proposed 
mechanisms that might contribute to neurodegeneration in MS and EAE.11 For example, 
MS patients develop antibodies to the ‘axolemma-enriched fraction’, neurofilaments 
(NFs) and neurofascin.196-200 In mice, immunization with NF-L protein resulted in spastic 
paraparesis concurrent with spinal cord axonal degeneration.200,201 The mice developed a 
pro-inflammatory T- cell response, and importantly, also developed antibodies to NF-L 
and IgG deposits within axons of spinal cord lesions.200,201 Further, MS patients were 
found to make antibodies to neurofascin 112,202, a protein with an isoform present on 
axons at the nodes of Ranvier.112,202 Application of these antibodies to hippocampal slice 
cultures inhibited axonal conduction. Following induction of EAE with myelin 
oligodendrocyte glycoprotein (MOG) specific T-cells, the addition of anti-neurofascin 
antibodies augmented disease.112,202 
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 MS patients (in contrast to healthy controls) have also been found to have 
antibodies to hnRNP A1, a ubiquitously expressed RNA binding protein (RBP) that is 
over expressed in neurons.11,12,94,95,192,193 Importantly, RBPs including hnRNP A1 
regulate RNA metabolism and dysfunctional RBPs have been shown to cause 
neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal lobe 
dementia (FTLD).132,184,203 The immunodominant epitope of hnRNP A1 recognized by 
MS IgG was experimentally determined to include ‘M9’, hnRNP A1’s nucleocytoplasmic 
shuttling domain, which is required for its transport into and out of the nucleus to the 
cytoplasm.11,12,204,205 In an in vitro model of neurodegeneration, anti-hnRNP A1 
antibodies that overlap the MS ‘M9’ immunodominant epitope caused neurodegeneration 
(as shown by Fluoro-jade C staining), apoptosis, and changes in gene expression related 
to hnRNP A1 function and the clinical phenotype of MS patients (ie. spastic paraparesis 
and ataxia).11,12,192 In separate in vitro experiments, anti-hnRNP A1 antibodies were 
found to enter neurons by utilizing endocytosis, a mechanism identical to antibodies 
isolated from ALS patients and monoclonal antibodies directed at Tau protein.11,206-208 
Further, the anti-hnRNP A1 antibodies caused the mis-localization of hnRNP A1 from 
predominantly nuclear to an equal nuclear/cytoplasmic distribution suggesting that the 
anti-hnRNP a1 antibodies bound M9 and disrupted hnRNP A1’s normal trafficking 
between the nucleus and cytoplasm.11,206 
 
 Considering these data, we hypothesized that anti-hnRNP A1 antibodies might 
promote neurodegeneration in vivo. We tested this hypothesis by injecting anti-hnRNP 
A1 antibodies in C57BL/6J mice with MOG-induced EAE. MOG-C57BL/6J EAE mice 
develop chronic disease with very little variation once peak disease has been achieved. A 
recent study meticulously mapped the timing of neurodegeneration of the entire central 
nervous system (CNS) using Fluoro-jade C, a marker of degenerating neural elements.148 
We paralleled this paradigm and found that the anti-M9 antibodies caused 
neurodegeneration in several neuronal pathways with a strong clinical correlation with 
signs and symptoms of MS patients. 
 
 
Results 
 
 
Anti-hnRNP A1-M9 Antibodies Exacerbate MOG35-55 Induced EAE 
 
 Following induction of EAE, mice were monitored daily for early clinical signs 
(limp tail) of EAE.  Upon first clinical signs of EAE, mice were injected with PBS 
(injection control), anti-mouse IgG2b (isotype control), or mouse anti-hnRNP A1 
antibodies (100 ug ip. every other day for a total of three injections).  Untouched non-
EAE C57BL/6J mice were used as a non-disease control.  Anti-hnRNP A1 antibody 
treated mice developed statistically worse clinical disease compared to all other groups 
(Figure 5-1).  Interestingly, anti-hnRNP A1 treated mice developed a more spastic gait 
compared to all other groups. In a typical experiment, 50% of the anti-hnRNP A1 
injected animals were spastic compared to only 10% of the mice in other EAE groups. 
Furthermore, several anti-hnRNP A1 mice had to be euthanized prior to the end of the  
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Figure 5-1. Clinical scores of EAE mice.   
EAE was induced in C57/Bl6 mice using MOG35-55/CFA and pertussis toxin.  On first 
signs of clinical symptoms, mice were given 100µg injections of PBS, IgG (MABC006), 
or anti-hnRNP A1 antibody (04-1469).  Injections were given every other day for a total 
of three injections.  EAE mice were scored daily from disease onset.  Clinical scoring 
was adapted from ‘Appendix A- EAE scoring guide’ found in the protocol of the Active 
Induction EAE Kit from Hooke Laboratories (Hooke cat no. EK-2110).  Generally 
speaking, the scoring was as follows: 1- limp tail, 2- hind limb weakness/wobbly gait, 3- 
hind limb paralysis, 4- hind limb paralysis/weakness of front limbs, 5- moribund.  
Animals were scored clinically throughout the study.  Anti-hnRNP A1-M9 antibody 
treated mice developed increased spasticity and paralysis compared to control groups.  
Quantification was performed in Graphpad Prism software. Statistical significance was 
analyzed by two-way repeated measures ANOVA using SEM. *P<0.05, **P<0.01.   
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study due to the severity of the spasticity and clinical disease, whereas mice in the other 
two groups did not commonly reach this severe disease state.  Additionally, in contrast to 
all other groups, some of the anti-hnRNP A1 mice developed tail lesions (30% of anti-
hnRNP A1 EAE compared to 0% of PBS or isotype control EAE).  Previously published 
studies have associated tail lesions in EAE with increased disease severity and immune 
responses209. Taken together, these data indicate that the anti-hnRNP A1 antibodies 
contributed to worsened clinical disease and a change in the phenotype of the mice 
(spastic compared to flaccid paralysis).   
 
 
Anti-hnRNP A1-M9 Antibodies Cause Increased Levels of Neurodegeneration of 
Specific CNS Pathways in EAE 
 
 Upon observing that anti-hnRNP A1 antibodies worsened EAE, we hypothesized 
that the augmented clinical progression might be related to changes in neurodegeneration 
in the CNS.  To examine this, we stained the brains and spinal cords of three animals 
from each group with Fluoro-jade C, a marker of degenerating neural elements. Fluoro-
jade C has been used previously to map neurodegeneration in the identical active  
MOG35-55 induced EAE protocol utilized in these studies. We compared data between 
groups and used the map of Fluoro-jade C neurodegeneration in EAE published by 
Brown and Sawchenko as reference.148  
 
 There was very minimal background Fluoro-jade C staining of non-neural 
elements in spinal cords or brains in untouched (non-EAE) animals as previously 
described (Figures 5-(2-5), ‘control’).148 In the spinal cords of the three EAE groups 
(PBS, isotype control IgG, anti-hnRNP A1), we found a similar distribution of staining 
(Figure 5-2). Staining (white punctates) dominated in the ventral spinocerebellar tracts 
(VSCT) at all levels of the spinal cord, with lesser amounts in the dorsal spinocerebellar 
tracts (DSCT). There was also a modest degree of staining in the posterior columns and 
throughout the grey matter of the spinal cord (Figure 5-2). There were no differences in 
Fluoro-jade C fluorescent intensity between the three EAE groups in the spinal cord 
(VSCT as an example, Figure 5-2). 
 
 Examination of the brainstems of these animals revealed neurodegeneration in the 
VSCT, trapezoid body, spinal tract of the trigeminal nerve, inferior cerebellar peduncle 
and other structures within the brainstem as described previously (Figure 5-3A and 
Table 5-1).148  There was an absence of staining in the superior cerebellar peduncle. 
There was neurodegeneration in the cerebellar peduncles that continued to include the 
pyramids (not shown) in all EAE induced animals.  The cerebellar peduncle data parallels 
that of Brown and Sawchenko (Table 5-1) 148, but the pyramidal data differs in that there 
was no reported Fluoro-jade C staining. Both involve the corticospinal system and these 
differences may be related to the length of the experiments (which were about a week 
longer than the experiments by Brown et al).  By comparing the neurodegeneration 
between EAE groups, it was determined that there was an increase in Fluoro-jade C 
staining in one specific tract, the VSCT, of the anti-hnRNP A1 antibody treated mice 
compared to the other EAE mice. The distal VSCT of the brainstem as it entered the  
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Figure 5-2. Fluoro-jade C staining of the spinal cord.  
Paraffin embedded brain sections from the lumbosacral region of the spinal cord were cut 
into 10µm sections.  Sections were stained for neurodegeneration using the Fluoro jade C 
neurodegeneration marker.  Zoomed images were taken from the ventral spinocerebellar 
tract cells of origin.  
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A. 
 
 
B. 
 
 
Figure 5-3. Fluoro-jade C staining of the ventral spinocerebellar tract of the brain 
stem.   
A. Fixed frozen brain sections from the brain stem were cut using a sliding microtome.  
Sections were cut at 30µm.  Sections were stained for neurodegeneration using Fluoro 
jade C neurodegeneration marker.  Zoomed image is taken from the area of the ventral 
spinocerebellar tract labeled with the arrow.  B.  Quantification of neurodegeneration was 
performed on 20 total images obtained from 3 animals per experimental group (20 
images per condition).  Mean fluorescence intensity was calculated using image J 
software.  Mean fluorescence intensities were compared using the student t-test using 
SEM. *P<0.05, **P<0.01.   
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Table 5-1. Areas of neurodegeneration in an antibody augmented model of EAE. 
 
 
 
Area of brain 
 
Neuro- 
degeneration 
Increased 
neurodegeneration 
in A1 mice 
Brain Stem Tracts   
Ventral Spinocerebellar Tract + + 
Trapezoid Body + - 
Spinal Tract of the Trigeminal Nerve + - 
Inferior Cerebellar Peduncle + - 
Pyramids + - 
Superior Cerebellar Peduncle - - 
Cerebellum   
Dentate Nucleus - - 
Interposed Nucleus - - 
Fastigial Nucleus - - 
Deep White Matter (arbor vitae) + + 
Cerebral Cortex   
Corpus Callosum + + 
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cerebellum parallel to the superior cerebellar peduncle showed increased 
neurodegeneration in anti-hnRNP A1 mice (Figure 5-3A and Table 5-1).  Quantitative 
analysis (10 images from each of 3 mice per group, total of 30 images per group) of 
Fluoro-jade C fluorescence using Image J software confirmed an increase in 
neurodegeneration in the anti-hnRNP A1 mice compared to all other groups (Figure 5-
3B).  The cells of origin of the VSCT are admixed with other neurons within layers VII, 
VIII and IX of the gray matter of the lumbosacral spinal cord.210-215 Some of the neurons 
are grouped into partially defined nuclei within layer VII including spinal border cells 
(SBCs), and the lumbar and sacral pre-cerebellar nuclei.214,216 Axons from these neurons 
immediately cross in the spinal cord at their level of origin in the ventral white matter. 
These projections make up the VSCT, which continues up the spinal column through the 
lateral funiculi, followed by the brainstem and then enters the cerebellum with the 
superior cerebellar peduncle, where its projections then enter the deep white matter of the 
cerebellum.210-215  With this in mind, we next examined the cerebellum for changes in 
neurodegeneration between the three EAE groups.  
 
 We observed large quantities of neurodegeneration in the deep white matter 
(arbor vitae) of the cerebellum (Figure 5-4 and Table 5-1).  Interestingly, both in this 
study as well as the study by Brown and Sawchenko 148, this area contains some of the 
most intense Fluoro-jade C staining of the CNS in EAE. Furthermore, in concordance 
with the data presented by Brown and Sawchenko, we also saw a lack of 
neurodegeneration in efferent pathways of the cerebellum including Purkinje cells and 
the interposed, fastigial, and dentate nuclei (Table 5-1).148  Comparison of all EAE 
groups as well as healthy controls revealed that there was increased neurodegeneration in 
the deep white matter (arbor vitae) of the cerebellum of anti-hnRNP A1 antibody treated 
animals compared to all other EAE groups (Figure 5-4A and Table 5-1).  This finding 
was quantified and confirmed using image J software, which showed a statistically 
significant increase in Fluoro-jade C staining in the anti-hnRNP A1 group (Figure 5-4B). 
There was minimal staining of the granule layer in the cerebellum, none of which 
included cell bodies. 
 
After investigating the brain stem and the cerebellum, we examined the cerebral 
cortex for changes in neurodegeneration. We observed identical patterns of 
neurodegeneration as published previously.148 We also witnessed neurodegeneration in 
the corpus callosum of all EAE induced mice (Table 5-1).148  Furthermore, we found that 
there was increased neurodegeneration in the genu of the corpus callosum of the anti-
hnRNP A1 antibody treated mice compared to all other groups (Figure 5-5A and Table 
5-1).  Again, this observation was confirmed by quantitative imaging (Figure 5-5B). 
 
 
Conclusions for Aim 3 
 
 Our data indicate that in EAE, an animal model of MS, antibodies to the ‘M9’ 
sequence of hnRNP A1 (compared to PBS and isotype matched IgG2b controls) caused: 
(1) worsened clinical disease, (2) an altered clinical phenotype (spastic paraparesis), (3) 
increased levels of neurodegeneration in the distal projection of the VSCT in the deep  
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Figure 5-4. Fluoro-jade C staining of the deep cerebellar white matter.   
A.  Fixed frozen brain sections from the cerebellum were cut using a sliding microtome.  
Sections were cut at 30µm.  Sections were stained for neurodegeneration using Fluoro 
jade C neurodegeneration marker.  Zoomed image is taken from the labeled area from the 
center of the white matter (labeled white line).  Cerebellar layers are labeled as follows: 
wm- white matter, gr- granular layer, p- purkinje cell layer, m- molecular layer.  Arrows 
represent the border of the deep white matter of the cerebellum (wm).  B.  Quantification 
of neurodegeneration was performed on 10 images from 3 animals per experimental 
group (30 images per condition).  Mean fluorescence intensity was calculated using 
image J software.  Mean fluorescence intensities were compared using the student t-test 
and SEM *P<0.05, **P<0.01.  
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A. 
 
 
B. 
 
 
Figure 5-5. Fluoro jade C staining of the corpus callosum.   
A. Fixed frozen brain sections from the cerebral cortex were cut using a sliding 
microtome.  Sections were cut at 30µm.  Sections were stained for neurodegeneration 
using Fluoro jade C neurodegeneration marker.  Images were taken from the genu of the 
corpus callosum adjacent to the lateral ventricle.  Zoomed images were taken from the 
center of the genu marked by an asterisk adjacent to the lateral ventricle.  B. 
Quantification of neurodegeneration was performed on 10 images from 3 animals per 
experimental group (30 images per condition).  Mean fluorescence intensity was 
calculated using image J software.  Mean fluorescence intensities were compared using 
the student t-test and SEM *P<0.05, **P<0.01.   
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white matter of the cerebellum and (4) increased levels of neurodegeneration in the genu 
of the corpus callosum. 
 
 We believe the results of these experiments are consistent with an antibody-
mediated autoimmune response to a CNS target that contributes to a ‘dying back’ 
mechanism of axonal degeneration. “Dying back,” describes length-dependent, distal to 
proximal, progressive axonal degeneration, which occurs in toxic, metabolic and 
neurodegenerative diseases.188,217-219  Although there was axonal degeneration within the 
proximal VSCT in the spinal cord, there were no differences between control and anti-
hnRNP A1 mice. The cells of origin of the VSCT are contained within laminae VII, VIII 
and IX of the lumbosacral spinal cord, thus the most proximal segments of the VSCT are 
in the spinal cord.210-215 Moving rostrally, neurodegeneration of the VSCT continued in 
both control and anti-hnRNP A1 mice in the brainstem, but again there were no 
differences between the groups. As the VSCT entered the cerebellum and continued in 
the arbor vitae (deep cerebellar white matter), the anti-hnRNP A1 mice showed 
significantly worse neurodegeneration than either of the control groups. These segments 
of the VSCT contain its most distal axons as they synapse on granule cells in the 
cerebellum. Considering there are no differences in proximal, but profound differences in 
distal segments of the VSCT, this is consistent with ‘dying back’ neurodegeneration 
(Figure 5-6).188,217-219  Importantly, the VSCT makes afferent connections to the 
corticospinal tract via cerebellar efferents (Figure 5-6). Considering that both cerebellar 
lesions and genetic mutations in diseases such as the inherited spastic ataxias cause 
changes in muscle tone 220-222, our data suggests that neurodegeneration of the VSCT 
might also contribute to spasticity, which was readily apparent in the anti-hnRNP A1 
antibody injected mice. These data add to the growing body of evidence that EAE is a 
suitable animal model to study neurodegeneration mechanisms that may be applicable to 
MS.148,194,195,223-225 
 
 Neurodegeneration is now believed to be the primary cause of permanent, long-
term disability in MS patients.187,188,192,193 Data indicate neuronal and axonal damage in 
an ongoing process in MS.7,9,13,186,187  In some patients, it begins during the relapsing, 
remitting phase of MS (RRMS) and continues into secondary progressive MS (SPMS). 
Neurodegeneration is also a common feature in MS patients without relapses (primary 
progressive MS (PPMS).187 Pathologically, neurodegeneration appears independent of 
plaque formation.18 For example, analysis of the corticospinal tract in the spinal cord of 
MS patients showed a significant reduction of nerve fiber density independent of cerebral 
plaque location.226-230  Interestingly, like the corticospinal tract, the spinocerebellar tracts 
are some of the longest of the CNS. Cerebellar symptoms are common and make major 
contributions to disability in MS patients.231 
 
 The brains and spinal cords of MS patients show evidence of both neuronal and 
axonal degeneration. For instance, there is neuronal loss and apoptosis of cortical 
pyramidal neurons.232  In addition, MS brains display markers of axonal degeneration 
including axonal dystrophy, axonal spheroids, and staining for non-phosphorylated 
neurofilament (SMI-32).7,9,18,186,191 These markers confirm the presence of axonal 
degeneration in MS, but do not implicate a specific mechanism.219 The cause of  
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Figure 5-6. Neural pathways related to the ventral spinocerebellar tract (VSCT). 
(1) Dorsal root ganglia synapse on the neuronal cell bodies of (2) the VSCT, which are 
contained within laminae VII, VIII and IX of lumbosacral levels of the spinal gray 
matter. Axons of the (2) VSCT, which are preferentially damaged by the anti-hnRNP A1-
M9 antibodies (green), cross in the spinal cord & pass through the deep cerebellar white 
matter to synapse on (3) granule cells. (3) Granule cells synapse on (4) Purkinje cells, 
which in turn, synapse in (5) deep cerebellar nuclei. (5) Deep cerebellar nuclei send 
efferent axons to (6) the thalamus, which relays information to (7) the motor cortex, 
which sends axons that synapse on (8) anterior horn cells in the ventral gray matter 
(lamina IX) of the spinal cord.  
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neurodegeneration appears to be multifactorial. In MS, there is evidence of both 
Wallerian Degeneration (transection of axons that disconnects the neuronal cell body 
from its distal axon) and ‘dying back’ pathologies.188,218,233,234 Both involve abnormalities 
in axonal transport, which is demonstrated by the accumulation of APP in axons of MS 
brains, which occurs in the setting of dysfunctional fast axonal transport.7,191,219  In 
animal models, axonal degeneration results from a specific sequence of events, which 
include impaired axonal transport, mitochondrial dysfunction and increase in intra-
axoplasmic calcium.218,225  Importantly, each of these abnormalities has been found in 
brains of MS patients as well as in EAE, and have been implicated in the pathogenesis of 
neurodegeneration. Several studies have shown that mitochondrial injury and associated 
oxidative damage, production of reactive oxygen species and induction of apoptosis 
contribute to axonal injury.13,17,235,236 Other studies implicate increased energy demands 
of demyelinating axons and the relative reduction of axonal ATP production, which 
results in a state of ‘virtual hypoxia’.38,237  In addition, there is evidence that 
neurodegeneration might result from lack of trophic support from myelin 8, inflammatory 
cytokines abnormal ion and sodium channel expression on axons 9,18,238, and calcium 
accumulation in damaged axons.9,237  
 
 Antibodies to CNS targets have been shown to contribute to neurodegeneration.11 
For example, in addition to antibodies to hnRNP A1, MS patients develop antibodies to 
NFs and neurofascin.11,112,200,202 In mice, immunization with NF-L caused antibody 
formation, IgG deposition on axons and spastic paraparesis concurrent with spinal cord 
axonal degeneration.200,201,239 In separate experiments, the addition of anti-neurofascin 
antibodies following induction of EAE with MOG specific T-cells, augmented disease 
and showed increased APP expression.112 Like antibodies to NF and neurofascin, the data 
presented here indicate that antibodies to hnRNP A1 contribute to neurodegeneration in 
EAE and because these antibodies are present in MS patients, strongly support their role 
in neurodegeneration in MS.11,12,94,95,192,193  We believe these data suggest that anti-
hnRNP A1 antibodies contribute to a ‘dying back’ mechanism of axonal degeneration. 
Although an exact mechanism in these experiments is not yet apparent, these data suggest 
that the site of attack of the anti-hnRNP A1 antibodies might be the cells of origins 
(neuronal cell bodies) of the VSCT, which are present in the lumbosacral spinal cord. In 
support of this hypothesis are two recent studies in EAE. The first showed that the VSCT 
is one of several pathways that is preferentially targeted by T-cells and activated 
microglia early in the course of EAE concurrent with neurodegeneration.148 Interestingly, 
similar findings were present in the corpus callosum 148, a common lesion site in MS 
patients. The second showed that entry of pathogenic Th1 and Th17 CD4+ T-
lymphocytes occurs at the L5 lumbar level, and that the damage present in EAE is 
initiated at this level of the CNS.240,241 We believe that both control and anti-hnRNP A1 
antibodies enter the CNS at this level of the spinal cord and that the anti-hnRNP A1 
antibodies specifically bind to the VSCT cells of origin (neuronal cell bodies). The anti-
hnRNP A1 antibodies causes changes in function of hnRNP A1 within the neuronal cell 
body (such as its mislocalization to the cytoplasm), which in turn contributes to distal 
axonal damage. M9 is hnRNP A1’s nucleocytoplasmic transport sequence and binds 
transportin, which together is part of the non-classical nucleocytoplasmic transport 
system.12,97,126,192,242-244  Disruption of the importin-mediated (‘classical’) 
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nucleocytoplasmic transport system results in neuronal degeneration.245-248  Recent data 
in our lab using an in vitro model of neurodegeneration showed that anti-hnRNP A1 
antibodies entered neurons and cause mis-localization of hnRNP A1 to the cytoplasm 
where it co-localized with stress granules and altered RNA metabolism of spastin.11,206 
Changes in spastin metabolism cause spasticity12,249, a feature of the animals in this 
study. Future studies are required to evaluate whether anti-hnRNP A1-M9 antibodies 
utilized the identical mechanism in vivo. 
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CHAPTER 6.    DISCUSSION 
 
 
Multiple Sclerosis (MS) is the most common autoimmune disorder of the central 
nervous system.  MS specifically targets and impairs the central nervous system (CNS) of 
the individual.  The disease course and severity of neurological disability is highly 
variable between individuals.  While the specific cause is unknown, MS is a multifaceted 
disorder thought to occur in individuals with a predisposed genetic susceptibility in which 
disease is triggered by an environmental factor such as altered metabolism, a virus, or 
other environmental factors.  Autoantibodies and their ability to target intracellular 
antigens have become an increasingly important area of research across autoimmune 
diseases.  The predominant theory comprises the idea that initial cellular injury 
predominates and is immediately followed by intracellular antigens being exposed to the 
adoptive immune response resulting in the ability of antibody response to the target 
antigen.  Autoantibodies have been implicated in a variety of autoimmune diseases such 
as SLE, RA, paraneoplastic disorders, MS, and HAM/TSP.     
 
 Patients with MS have been shown to produce autoantibodies to the RNA binding 
protein hnRNP A1.  It is important to note that patients with other neurologic diseases 
and normal controls do not produce autoantibodies to this protein.  hnRNP A1 is an RNA 
binding protein highly expressed in neurons.  hnRNP A1 functions in pre-mRNA 
splicing, RNA metabolism, and nuclear/cytoplasmic trafficking of mature mRNA to sites 
of translation.  hnRNP A1 is a 320 amino acid protein with several functional motifs.  
The N-terminus of hnRNP A1 is composed of a 185 amino acid residue comprising two 
90 amino acid repeats which function as RNA recognition motifs (RRM) or RNA binding 
domains (RBD).  The remaining C-terminus of hnRNP A1 comprises the remaining 135 
residues.  The C-terminal region is composed of a glycine rich region encoding an RGG 
box whose functionality includes RNA binding, protein-protein interactions, nuclear 
localization, and RNA strand annealing activity.  Nearing the end of the C-terminus is the 
M9 sequence composing amino acids 268-305.  The M9 region serves as the nuclear 
export sequence/nuclear localization sequence (NES/NLS) of the protein.  The remaining 
amino acid residue at the C-terminus of the protein comprises the F peptide (aa 305-320), 
which must be phosphorylated to initiate the binding of hnRNP A1 to transportin 1 
(Trn1), which is necessary for nuclear/cytoplasmic transport.  It is important to note that 
patients with MS produce autoantibodies that present specificity to the M9 region of 
hnRNP A1. 
 
 Although it had been shown that MS patients produce autoantibodies to hnRNP 
A1, not much had been elucidated regarding mechanism.  We sought to reveal the 
mechanism by which trafficking of anti-hnRNP A1 specific antibodies occurs as well as 
possible downstream effects due to the specificity of anti-hnRNP A1 antibodies.  
Previously it has been published that anti-recoverin antibodies, present in patients with 
cancer associated retinopathy (CAR), penetrate E1A.NR3 cells through endocytosis 250.  
We have published data presenting a similar mechanism of entry utilized by anti-hnRNP 
A1 antibodies into neuronal cells.  Through colocalization studies as well as studies 
utilizing agents to block various forms of endosomal entry, we determined that anti-
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hnRNP A1 antibodies penetrate neuronal cells via clathrin-mediated endocytosis. In 
comparison to control IgG, anti-hnRNP A1 specific antibodies penetrated neuronal cells 
more readily and exhibited a higher level of colocalization with early endosomes.  Since 
endocytosis is a general method of cellular uptake of a variety of molecules across 
various neuronal cell types, antibody penetration could be occurring across a multitude of 
cell types.  
 
 In addition to determining mechanism of antibody entry, we sought to determine 
any downstream effects that could be occurring due to antibody specificity.  We worked 
to determine if any changes in cellular viability were present due to the addition of anti-
hnRNP A1 specific antibodies compared to control IgG.  We determined the viability of 
the neuronal cells based upon three measures of overall cell health: caspase 3/7 activity as 
a measure of apoptosis, cytotoxicity of the cell, and ATP levels of the cell.  Although 
there was no differences in cytotoxicity of the cells between groups, we do present data 
representing a significant increase in caspase 3/7 activity resulting in increased apoptosis 
and a significant decrease in ATP levels of anti-hnRNP A1 antibody treated cells 
compared to IgG treated and control cells.  Studies have shown that decreases in ATP 
levels often correlates with initiation of apoptosis leading to cell death 172.  In addition to 
the altered cellular viability presented, we also present the effect of anti-hnRNP A1 
antibodies upon endogenous hnRNP A1 protein.  Anti-hnRNP A1 antibodies exhibited a 
specific effect upon the endogenous protein resulting in redistribution of hnRNP A1 from 
a predominantly nuclear localization to a near equal nuclear to cytoplasmic redistribution.  
It is important to note that the epitope recognized by the anti-hnRNP A1 antibodies is 
specific to amino acids 293-304, the M9 region of hnRNP A1, which serves as the 
NES/NLS 11.  Studies have shown that deletion mutations within this region of M9 result 
in loss of nuclear import and export function of hnRNP A1 protein 126.  Taken together, 
we believe that anti-hnRNP A1 antibodies specificity to the M9 region results in antibody 
binding to this sequence resulting in similar loss of function as shown by deletion 
mutations of this region.  
 
 In order to further explore the effect of anti-hnRNP A1 antibodies upon cell 
viability, we examined cellular trafficking of the antibodies after release from early 
endosomes.  Based upon the altered cellular viability of the cells due to antibody 
presence, we believed that the presence of antibodies would cause formation of stress 
granules within the neuronal cells.  In order to determine trafficking of antibodies within 
neuronal granules, we needed to perform colocalization studies labeling the three typed 
of neuronal granules: stress granules (SGs), processing bodies (P bodies), and neuronal 
transport granules 179.  Stress granule formation occurs within cells due to various cellular 
stressors and act to harbor various RNA binding proteins and their translationally arrested 
mRNA cargo 179.  Once the cell has regained a state of homeostasis, SGs sort, remodel, 
and export their mRNA cargo for reinitiation or storage 179.  P bodies act as sites of 
translational repression and degradation for the cell 179.  Neuronal granules are transport 
granules of the neuron and are utilized to transport various mRNA cargo along the axon 
to various sites of translation 179. Our studies revealed that anti-hnRNP A1 antibodies as 
well as control IgG caused stress granule formation within neuronal cells.  Additionally, 
both anti-hnRNP A1 antibodies as well as control IgG colocalized within SGs, however, 
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anti-hnRNP A1 antibodies colocalized more readily than control IgG.  Furthermore, 
neither anti-hnRNP A1 antibodies nor control IgG colocalized with either P bodies or 
neuronal transport granules.  Our studies suggest that antibodies contain specificity in 
binding SGs once they have trafficked into the cytoplasm of neuronal cells.  
 
Based upon our findings, we believed that anti-hnRNP A1 antibodies might have 
a specific effect upon bound mRNA cargoes of hnRNP A1 protein.  During the cellular 
stress response hnRNP A1 protein enters stress granules, thus protecting its mRNA cargo 
in a state of translational repression 179.  Since anti-hnRNP A1 antibodies are also present 
within stress granules we determined specific mRNA binding partners as well as possible 
downstream effects of anti-hnRNP A1 antibodies upon these mRNAs.  Through RNA 
immunoprecipitation studies utilizing qRT-PCR, we determined that spastin (SPG4) and 
paraplegin (SPG7) are mRNA binding partners of hnRNP A1 protein.  Previous studies 
have shown that neurons transfected with anti-hnRNP A1 antibodies had altered levels of 
SPG4 and SPG7 compared to controls 12.  Furthermore, IgG isolated from MS patients 
presented lowered levels of SPG4 and SPG7 compared to controls when analyzed by RT-
PCR 12.  Our studies further strengthened the link between anti-hnRNP A1 antibodies and 
SPG4 and SPG7.  We present Western blot data revealing translational repression of 
SPG4 and SPG7 due to anti-hnRNP A1 antibody addition to neuronal cells.  It is 
important to note that mutations in SPG4 and SPG7 result in various form of HSP, a 
genetically inherited spastic disorder which is clinically similar to some forms of MS 133.  
Mutations in SPG4 account for the most common autosomal dominant form of HSP 133.  
SPG7 is associated with mitochondrial function, specifically being implicated in 
mitochondrial chain complexes I and IV 185.  Patients with HSP resulting from mutations 
in SPG7 have been shown to have a significant decrease in mitochondrial chain 
complexes I and IV 185.  Taken together with the previous data presenting altered levels 
of cellular ATP due to anti-hnRNP A1 addition to neuronal cells, we provide a possible 
mechanism for ATP depletion.  It appears that anti-hnRNP A1 antibodies cause 
translational repression of various mRNA binding partners of hnRNP A1, specifically 
SPG7.  We hypothesize that the reduction of SPG7 protein levels further causes a 
depletion of mitochondrial chain complexes I and IV similar to what is seen in HSP 
patients with mutations in SPG7.  Depletion of mitochondrial chain complexes I and IV 
would result in depletion of ATP levels in the effects cells.  We hypothesize that the 
suggested mechanism of altered cellular viability due to depletion of ATP levels could 
result in neurodegeneration of effected neuronal cells.  
 
We further explored the question of neurodegeneration in an animal model of MS.  
We employed the experimental autoimmune encephalomyelitis (EAE) murine model of 
MS.  Disease was initiated in the animals followed by treatment with anti-hnRNP A1-M9 
specific antibodies (whose epitope overlap the immunodominant epitope recognized by 
IgG isolated from MS patients) compared to normal control IgG as well as diseased 
animals with no antibody addition.  Clinical scoring of the animals throughout disease 
revealed that anti-hnRNP A1 antibody specificity worsens clinical symptoms resulting in 
a ‘spastic’ disease state compared to controls.  Furthermore, anti-hnRNP A1 antibody 
treated EAE mice show increased neurodegeneration by Fluoro-jade C neurodegeneration 
staining compared to controls.  Specifically, anti-hnRNP A1 antibodies caused increased 
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neurodegeneration in the genu of the corpus callosum, deep white matter (arbor vitae) of 
the cerebellum, and the ventral spinocerebellar tract of the brain stem. To sum up our 
findings in an antibody treated EAE model of MS, anti-hnRNP A1-M9 antibody 
treatment caused: 1) worsened clinical disease 2) altered clinical phenotype resulting in 
spastic paraparesis 3) increased neurodegeneration in the distal projection of the VSCT in 
the deep white matter of the cerebellum and 4) increased levels of neurodegeneration in 
the genu of the corpus callosum.   
 
 We believe that the data presented supports a ‘dying-back’ mechanism of 
neurodegeneration due to an antibody-mediated autoimmune response on the CNS.  
‘Dying back’ axonal degeneration is described as a distal to proximal degeneration of the 
axon due to metabolic, toxic, and neurodegenerative diseases 188,217-219.  Specifically 
within our model system we describe the most proximal portion of the VSCT, the VSCT 
cells of origin the spinal cord, as showing no differences in neurodegeneration between 
anti-hnRNP A1 treated mice compared to controls.  The VSCT cells of origin are the 
most proximal segment of the VSCT contained within laminae VII, VIII, and IX of the 
lumbosacral spinal cord 210-215.  As we move rostrally, neurodegeneration of the VSCT 
increased, however there were no differences between the groups in the brainstem.  As 
we continue rostrally, neurodegeneration increases and we witness a significant increase 
in neurodegeneration of anti-hnRNP A1 antibody treated mice as the VSCT enters the 
cerebellum and projects into the deep white matter (arbor vitae) of the cerebellum.  These 
segments of the VSCT contain the most distal axons as they synapse on the granular cells 
of the cerebellum.  Importantly, the increased neurodegeneration we show in the distal 
VSCT projections compared to the proximal segments of the VSCT are consistent with 
the ‘dying back’ neurodegeneration phenomena 188,217-219.  Furthermore, the VSCT makes 
afferent connections to the corticospinal tract via cerebellar efferents.  Similar to 
cerebellar lesions and inherited spastic ataxias causing changes in muscle tone, we 
suggest that antibody-mediated neurodegeneration of the VSCT might also contribute to 
neurodegeneration as evidenced by anti-hnRNP A1 antibody treated EAE mice.   
 
 In summary, we have presented data implicating anti-hnRNP A1 antibodies in the 
neurodegeneration seen in an EAE model of MS.  We have provided evidence of 
worsened clinical phenotype resulting in ‘spasticity’ of anti-hnRNP A1 antibody treated 
animals. Furthermore, we have correlated worsened phenotype with increased 
neurodegeneration of the afferent tracts of the VSCT projecting into the deep white 
matter of the cerebellum in a ‘dying back’ type phenomena.  Our in vitro studies have 
further provided a mechanism to explain the antibody-induced neurodegeneration.  We 
have mapped the mechanism of antibody entry through clathrin-mediated endocytosis.  
Data has been presented exhibiting deleterious effects of anti-hnRNP A1 antibodies 
including redistribution of endogenous hnRNP A1 protein, decreased cellular ATP levels, 
and increased apoptosis.  Additionally, we have evidence suggesting a mechanism by 
which anti-hnRNP A1 antibodies alter cellular viability leading to neurodegeneration.  
Our data suggest that anti-hnRNP A1 antibodies enter neuronal cells via clathrin-
mediated endocytosis.  Once inside the cell, antibodies cause cellular stress resulting in 
formation of SGs to which antibodies localize.  Furthermore, anti-hnRNP A1 antibodies 
presence results in a redistribution of endogenous hnRNP A1 from a primarily nuclear to 
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an equal nuclear to cytoplasmic redistribution.  The antibody presence has an effect upon 
bound mRNA binding partners of hnRNP A1 protein, specifically SPG4 and SPG7 
mRNA.  The antibody effect results in translational repression of SPG4 and SPG7.  
Similar to mutations in SPG7 resulting in depletion of mitochondrial chain complexes I 
and IV, we hypothesize that translational repression of SPG7 results in depleted 
mitochondrial chain complexes I and IV.  Depletion of these complexes would result in 
depleted ATP levels leading to apoptosis and ultimately neurodegeneration as seen in the 
EAE model.  Further work needs to be completed to gain further insight into the 
intricacies of the antibody-mediated neurodegeneration witnessed throughout our studies, 
however the work at hand has laid the groundwork for further investigation towards a 
possible treatment pertaining to the neurodegeneration present in MS. 
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